<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25045405</article-id><article-id pub-id-type="pmc">4100318</article-id><article-id pub-id-type="publisher-id">alzrt272</article-id><article-id pub-id-type="doi">10.1186/alzrt272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeting the proper amyloid-beta neuronal toxins: a path forward for
Alzheimer&#x02019;s disease immunotherapeutics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Goure</surname><given-names>William F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>wgoure@acumenpharm.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Krafft</surname><given-names>Grant A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gkrafft@acumenpharm.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Jerecic</surname><given-names>Jasna</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jasna@calsynapse.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Hefti</surname><given-names>Franz</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fhefti@acumenpharm.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Acumen Pharmaceuticals, Inc., 4453 North First Street, #360, Livermore, CA 94551,
USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>7</month><year>2014</year></pub-date><!-- PMC Release delay is 12 months and 0 days and was based on the epub date.--><pub-date pub-type="pmc-release"><day>9</day><month>7</month><year>2015</year></pub-date><volume>6</volume><issue>4</issue><fpage>42</fpage><lpage>42</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Goure et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Goure et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>The licensee has exclusive rights to distribute this article, in any medium, for 12
months following its publication. After this time, the article is available under the
terms of the Creative Commons Attribution License
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited. The Creative Commons Public Domain Dedication waiver
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data
made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/6/4/42"/><abstract><p>Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer&#x02019;s
disease brain are orders of magnitude greater than soluble amyloid-beta oligomer
levels. Monomeric amyloid-beta has no known direct toxicity. Insoluble fibrillar
amyloid-beta has been proposed to be an <italic>in vivo</italic> mechanism for removal of
soluble amyloid-beta and exhibits relatively low toxicity. In contrast, soluble
amyloid-beta oligomers are widely reported to be the most toxic amyloid-beta form,
both causing acute synaptotoxicity and inducing neurodegenerative processes. None of
the amyloid-beta immunotherapies currently in clinical development selectively target
soluble amyloid-beta oligomers, and their lack of efficacy is not unexpected
considering their selectivity for monomeric or fibrillar amyloid-beta (or both)
rather than soluble amyloid-beta oligomers. Because they exhibit acute,
memory-compromising synaptic toxicity and induce chronic neurodegenerative toxicity
and because they exist at very low <italic>in vivo</italic> levels in the Alzheimer&#x02019;s
disease brain, soluble amyloid-beta oligomers constitute an optimal immunotherapeutic
target that should be pursued more aggressively.</p></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD) is the most common form of dementia, accounting for 60%
to 80% of all dementias [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Worldwide, the prevalence of dementia was more than 35 million in 2010, and
projections exceed 65 million by 2030 and 115 million by 2050 [<xref ref-type="bibr" rid="B1">1</xref>]. Significantly, no drugs that prevent or slow the progression of AD are
currently approved. The development of effective AD therapeutics is clearly a tremendous
medical challenge and should be one of society&#x02019;s top medical priorities.</p><p>Despite the great need and significant societal and financial incentives, many
pharmaceutical companies and investors have reduced investments in the search for new AD
drugs, citing recent clinical failures of several high-profile experimental AD
therapeutics and the high risks and costs of such development endeavors. The recent
clinical failures also have intensified scrutiny of the &#x02018;amyloid cascade
hypothesis&#x02019;, which spawned many of the recent experimental AD drugs targeting the
amyloid-beta (A&#x003b2;) peptide. Nevertheless, the causal linkage between A&#x003b2; and AD
remains strong and is supported by hundreds of studies over the past two decades [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. (This is a representative sample of published reviews, and apologies are
given to the authors of many excellent reviews that are not cited.)</p><p>Essentially all A&#x003b2; therapeutic approaches so far have targeted reducing the levels
of A&#x003b2; monomer or A&#x003b2; deposits (or both) in the brain. However, today, the
causal role of A&#x003b2; in AD is widely considered to involve soluble A&#x003b2; oligomers,
and therapeutic strategies that selectively target soluble A&#x003b2; oligomers offer the
potential to deliver rapid symptomatic benefit and long-term disease modification. This
review describes the role of soluble A&#x003b2; oligomers within the amyloid hypothesis and
discusses implications for current A&#x003b2; immunotherapies and new immunotherapies
directed selectively toward soluble A&#x003b2; oligomers.</p></sec><sec><title>The amyloid cascade hypothesis</title><p>The first suggestion of an &#x02018;amyloid hypothesis&#x02019; to explain the pathology of
AD was that of Wong and colleagues [<xref ref-type="bibr" rid="B11">11</xref>], who postulated that A&#x003b2;-derived cerebrovascular amyloid caused seepage
of A&#x003b2; and other substances from plasma into the brain, leading to the formation of
A&#x003b2; plaques and possibly neurodegeneration. This was revised into the more
well-known amyloid cascade hypothesis that proposed that deposition of A&#x003b2; as
neuritic plaques caused AD and led to neurofibrillary tangles, cell loss, vascular
damage, and dementia [<xref ref-type="bibr" rid="B12">12</xref>]. The amyloid hypothesis linking A&#x003b2; to AD catalyzed much of AD and
A&#x003b2; research over the past two decades, and key studies during that period led to
important revisions of the hypothesis that highlighted the central role of soluble
A&#x003b2; oligomers in synaptic dysfunction and loss [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B19">19</xref>].</p><p>The current understanding of the A&#x003b2; cascade is derived primarily from <italic>in
vitro</italic> studies, the vast majority of which were conducted by using A&#x003b2;
concentrations orders of magnitude greater than those found <italic>in vivo</italic>. The
assembly of A&#x003b2; peptides to form soluble oligomers, protofibrils, and fibrils is
well documented to be affected by the isoform of the starting peptide, how the peptide
is treated prior to assembly, the nature of the buffer, pH, peptide concentration,
assembly temperature and time, agitation, and presence of other peptides or biological
materials [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. Moreover, preparations of soluble A&#x003b2; species have been shown to change
with time or upon dilution in different buffers, particularly in cell culture media [<xref ref-type="bibr" rid="B19">19</xref>]. Thus, caution must be taken in extrapolating the results and conclusions of
<italic>in vitro</italic> studies to <italic>in vivo</italic> reality. Although precise mechanistic
details remain to be elucidated, a multitude of studies by numerous researchers support
the conclusion that monomeric A&#x003b2; peptides assemble to form soluble A&#x003b2;
oligomers, which further aggregate to form fibrillar A&#x003b2; [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Three distinct pools of A&#x003b2; species exist: A&#x003b2; monomers, soluble A&#x003b2;
oligomers, and insoluble fibrillar A&#x003b2;. Each of these pools encompasses an array of
individual species. Thus, monomeric A&#x003b2; peptides encompass various isoforms,
including A&#x003b2;(1-40), A&#x003b2;(1-42), and A&#x003b2;(1-43), as well as numerous
N-terminal truncated isoforms. (For example, see the introductory paragraphs of Tekirian
and colleagues [<xref ref-type="bibr" rid="B26">26</xref>].) Insoluble fibrillar A&#x003b2; aggregates are also known to be heterogeneous
in structure and composed of various A&#x003b2; isoforms, both full-length as well as
N-terminal and C-terminal truncated isoforms. (For example, see the introductory
paragraphs of Roher and colleagues [<xref ref-type="bibr" rid="B27">27</xref>] and Thal and colleagues [<xref ref-type="bibr" rid="B28">28</xref>].)</p><p>Soluble A&#x003b2; oligomers are also heterogeneous and perhaps more ambiguous because of
the different terminologies used by different researchers to describe them. (For an
excellent review of soluble A&#x003b2; oligomers, see Benilova and colleagues [<xref ref-type="bibr" rid="B9">9</xref>].) Thus, soluble A&#x003b2; oligomer species reported by various researchers have
been termed sodium dodecyl sulfate (SDS)-stable A&#x003b2; oligomers [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>], low-n-oligomers [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>], dimers [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>], trimers [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B38">38</xref>], tetramers [<xref ref-type="bibr" rid="B37">37</xref>], paranuclei [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>], dodecamers and A&#x003b2;*56 [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>], amyloid-derived diffusible ligands (ADDLs) [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B44">44</xref>], A&#x003b2; oligomers [<xref ref-type="bibr" rid="B45">45</xref>], prefibrillar oligomers [<xref ref-type="bibr" rid="B46">46</xref>], A&#x003b2; globulomers [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B47">47</xref>-<xref ref-type="bibr" rid="B49">49</xref>], spherical oligomers [<xref ref-type="bibr" rid="B50">50</xref>], amylospheroids [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>], protofibrils [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref>], and annular protofibrils [<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B56">56</xref>]. Most of these terminologies refer to a mixture of metastable, soluble
A&#x003b2; oligomer species in equilibrium rather than a discrete, stable species. In many
cases, there is similarity in the species comprising the different preparations. In this
review, we will use the terminology soluble A&#x003b2; oligomers to describe A&#x003b2;
species composed of more than one A&#x003b2; peptide that remain in solution following
centrifugation. A&#x003b2; fibrils or fibrillar A&#x003b2; will be used as a general
description of insoluble A&#x003b2; plaques and vascular amyloid. (The term A&#x003b2; plaques
rather than amyloid plaques will be used to more precisely describe amyloid plaques
comprising primarily A&#x003b2; peptides versus those comprising primarily non-A&#x003b2;
peptides.)</p><p>It has been established that the levels of A&#x003b2; monomer and deposited fibrillar
A&#x003b2; in the AD brain are orders of magnitude greater than soluble A&#x003b2; oligomer
levels [<xref ref-type="bibr" rid="B57">57</xref>-<xref ref-type="bibr" rid="B65">65</xref>]. However, more than three decades of intense investigation has not provided a
precise understanding of the extent of interconversion among the various A&#x003b2;
species.</p><p>A&#x003b2; dimers have been demonstrated to form at physiologically relevant concentrations
of A&#x003b2; monomer <italic>in vivo</italic>[<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B67">67</xref>]. Numerous <italic>in vitro</italic> studies have shown that soluble A&#x003b2; oligomers
and protofibrils form under similar conditions and that both species can proceed to form
larger fibrillar species [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B68">68</xref>-<xref ref-type="bibr" rid="B74">74</xref>]. More recent studies provide further support for the addition of soluble
A&#x003b2; oligomers to protofibrillar and fibrillar assemblies and also provide data
indicating that oligomerization can occur via a secondary nucleation mechanism caused by
fibrillar A&#x003b2; [<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B74">74</xref>], possibly suggesting a mechanistic linkage between fibrillar A&#x003b2; and
soluble A&#x003b2; oligomers. However, the precise mechanism of <italic>in vivo</italic> fibril
formation has not been fully established.</p><p>A&#x003b2; plaques are now generally considered to be a relatively benign species [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B75">75</xref>]; however, whether A&#x003b2; plaques are a sink or a source for toxic soluble
A&#x003b2; oligomers is a subject of debate. Several studies with &#x003b3;-secretase
inhibitors [<xref ref-type="bibr" rid="B76">76</xref>-<xref ref-type="bibr" rid="B79">79</xref>] and two studies in transgenic mice that overexpress mutant amyloid precursor
protein (APP) via a doxycycline-regulated promoter [<xref ref-type="bibr" rid="B80">80</xref>,<xref ref-type="bibr" rid="B81">81</xref>] show that subchronic or chronic suppression of A&#x003b2; production arrested
A&#x003b2; plaque formation but did not result in observable clearance of existing plaques.
In a related study [<xref ref-type="bibr" rid="B82">82</xref>], A&#x003b2;(1-42) immunization of Tg2576 mice prior to significant A&#x003b2;
deposition, at an age with modest deposition or at an age with significant deposition,
showed that immunization prevented additional A&#x003b2; deposition but did not result in
significant clearance of pre-existing A&#x003b2;. These studies indicate that mature,
dense-core A&#x003b2; plaques are not in significant equilibrium with soluble A&#x003b2;
pools. Studies in transgenic mouse models of AD reporting decreased soluble A&#x003b2;
oligomer levels and reduced cognitive deficits with increasing A&#x003b2; plaque levels
also provide support for the concept that A&#x003b2; plaques may be a sink for soluble
A&#x003b2; species [<xref ref-type="bibr" rid="B83">83</xref>,<xref ref-type="bibr" rid="B84">84</xref>].</p><p>However, in an elegant study in APP transgenic mice using a novel microdialysis
technique, the half-life of low-molecular-weight A&#x003b2; species in hippocampal
interstitial fluid following inhibition of A&#x003b2; production by a potent secretase
inhibitor was doubled in 12- to 15-month-old mice with A&#x003b2; deposits compared with
3-month-old mice without A&#x003b2; deposits [<xref ref-type="bibr" rid="B85">85</xref>]. On the basis of these results, it was suggested that insoluble A&#x003b2; was
in equilibrium with soluble A&#x003b2; in the interstitial fluid. In a related study using
similar techniques, the temporal changes of low-molecular-weight A&#x003b2; species in
interstitial fluid and A&#x003b2; levels in Tris-buffered saline (TBS), SDS, and formic
acid extracts of brain tissues of 3-, 12-, and 24-month-old APP transgenic mice were
reported [<xref ref-type="bibr" rid="B86">86</xref>]. A significant age-dependent decrease in low-molecular-weight A&#x003b2; in
interstitial fluid and significant increases in A&#x003b2; species in SDS and formic acid
extracts of brain tissues were found. Although A&#x003b2; increased approximately
seven-fold from baseline in the TBS extract of brain tissues, the level of A&#x003b2; in
TBS extracts was less than 2% of the total A&#x003b2; in SDS and formic acid extracts.
These results indicated an age-dependent sequestration of A&#x003b2; as non-diffusible cell
matrix and membrane-bound A&#x003b2; and deposited A&#x003b2; plaques. Acute &#x003b3;-secretase
inhibition of A&#x003b2; production in plaque-free and plaque-rich mice suggested that
A&#x003b2;(1-42) in the interstitial fluid of plaque-rich mice was derived primarily from
A&#x003b2;(1-42) sequestered in brain parenchyma rather than from new biosynthesis.
However, it was not possible to determine whether cell matrix and membrane-bound A&#x003b2;
or A&#x003b2; plaques or both forms of A&#x003b2; were the source of A&#x003b2;(1-42) in the
interstitial fluid of aged mice.</p><p>In a more recent study of the temporal changes of A&#x003b2; species in the interstitial
fluid and brain tissues of APP transgenic mice, Takeda and colleagues [<xref ref-type="bibr" rid="B87">87</xref>], using a 1,000-kDa-molecular-weight cutoff microdialysis probe, reported the
temporal changes in soluble A&#x003b2; oligomer levels. In that study, consistent with
previous studies [<xref ref-type="bibr" rid="B85">85</xref>,<xref ref-type="bibr" rid="B86">86</xref>], a significant, age-dependent increase in A&#x003b2; levels in TBS and formic
acid extracts of brain tissues was found, and TBS extractable A&#x003b2; was less than 1%
of formic acid extractable A&#x003b2;. However, unlike previous studies using a
35-kDa-molecular-weight cutoff microdialysis probe [<xref ref-type="bibr" rid="B85">85</xref>,<xref ref-type="bibr" rid="B86">86</xref>], a significant, age-dependent increase in interstitial fluid A&#x003b2; levels
was found by using the larger-pore-sized microdialysis probe. The majority of the
A&#x003b2; in interstitial fluid was determined to be higher-molecular-weight soluble
A&#x003b2; oligomers, which showed an age-dependent increase relative to
lower-molecular-weight A&#x003b2; species. Temporal changes in soluble A&#x003b2; oligomer
levels in interstitial fluid and TBS brain extracts showed a significant positive
correlation with formic acid A&#x003b2; extract levels. Comparison of high- and
low-molecular-weight interstitial fluid A&#x003b2; levels at baseline and following acute
treatment with a &#x003b3;-secretase inhibitor showed slower clearance of
higher-molecular-weight A&#x003b2; oligomers compared with low-molecular-weight A&#x003b2;
species.</p><p>Narayan and colleagues [<xref ref-type="bibr" rid="B88">88</xref>] have recently used single-molecule imaging techniques to investigate
interactions between A&#x003b2; peptides and hippocampal cell membranes and reported
results indicating that A&#x003b2; oligomers preferentially interact with membranes
compared with A&#x003b2; monomer, thereby providing support for the results observed in the
microdialysis studies. Thus, this study, coupled with those of the temporal changes of
A&#x003b2; species in APP transgenic mice [<xref ref-type="bibr" rid="B85">85</xref>-<xref ref-type="bibr" rid="B87">87</xref>], does not resolve the controversy regarding the sink/source relationship
between fibrillar and soluble A&#x003b2; species.</p><p>The sink/source relationship between soluble and insoluble A&#x003b2; pools is complex, not
fully understood, and subject to ongoing debate. Two different forms of A&#x003b2; plaques
are present in the AD brain: vascular amyloid plaques that are primarily composed of
A&#x003b2;(1-40) and A&#x003b2; plaques that are primarily composed of A&#x003b2;(1-42) [<xref ref-type="bibr" rid="B89">89</xref>]. <italic>In vitro</italic> studies have shown that fibrillar A&#x003b2;(1-40) and
A&#x003b2;(1-42) are in equilibrium with soluble A&#x003b2; [<xref ref-type="bibr" rid="B90">90</xref>,<xref ref-type="bibr" rid="B91">91</xref>] but that recycling of A&#x003b2;(1-40) fibrils is significantly faster that
A&#x003b2;(1-42) fibrils [<xref ref-type="bibr" rid="B91">91</xref>]. Moreover, it has been reported that plaque deposition proceeds in two
distinct kinetic phases: an initial, reversible deposition phase followed by a
time-dependent irreversible deposition phase [<xref ref-type="bibr" rid="B92">92</xref>]. Furthermore, a recent study of the rates of formation of A&#x003b2; oligomers
and fibrils provided evidence that the formation of soluble A&#x003b2; oligomers from
monomeric A&#x003b2; is catalyzed by fibrillar A&#x003b2; [<xref ref-type="bibr" rid="B73">73</xref>]. This study not only indicated a mechanistic linkage between soluble A&#x003b2;
oligomers and fibrillar A&#x003b2; but also provided evidence showing that fibrillar
A&#x003b2; can be a &#x02018;source&#x02019; of soluble A&#x003b2; via catalyzed oligomerization
of A&#x003b2; monomer rather than via a disaggregation process. This study also provided an
alternative explanation for the study by Koffie and colleagues [<xref ref-type="bibr" rid="B93">93</xref>], who reported a halo of soluble A&#x003b2; oligomers surrounding A&#x003b2; plaques
and proposed that A&#x003b2; plaques were a possible source of soluble A&#x003b2;
oligomers.</p><p>Although precise details remain to be fully elucidated, collectively, over two decades
of studies on the mechanisms of formation of oligomeric and fibrillar A&#x003b2;, the
temporal distribution of A&#x003b2; species <italic>in vitro</italic> and <italic>in vivo</italic>, the
age-dependent effect of A&#x003b2; immunization, and the effects of subchronic and chronic
suppression of A&#x003b2; production upon <italic>in vivo</italic> A&#x003b2; plaque levels show a
significant, age-dependent increase in brain levels of soluble A&#x003b2; oligomers and
deposited fibrillar A&#x003b2;. Collectively, the studies suggest that mature, dense-core
A&#x003b2; plaques are not in equilibrium to any significant extent with soluble pools of
A&#x003b2;, but that A&#x003b2; sequestered in the cell matrix and membranes and immature
plaques is in equilibrium with soluble A&#x003b2; pools, and that fibrillar A&#x003b2;
catalyzes A&#x003b2; monomer oligomerization, giving rise to soluble A&#x003b2; oligomers and
growth of A&#x003b2; plaques.</p></sec><sec><title>Neuronal toxicity of amyloid-beta species</title><p>Monomeric A&#x003b2;, primarily the A&#x003b2;(1-40) and A&#x003b2;(1-42) peptides, is produced
in various cell types throughout the body and reported to have trophic properties <italic>in
vitro</italic>[<xref ref-type="bibr" rid="B94">94</xref>,<xref ref-type="bibr" rid="B95">95</xref>]. There are no reports suggesting that monomeric A&#x003b2; possesses any direct
cellular toxicity at physiologically relevant concentrations. Insoluble fibrillar
aggregates of A&#x003b2;, vascular amyloid and A&#x003b2; plaques, exhibit relatively low
<italic>in vitro</italic> toxicity and have been proposed to be an <italic>in vivo</italic> mechanism
for removal of the more toxic soluble A&#x003b2; species [<xref ref-type="bibr" rid="B83">83</xref>,<xref ref-type="bibr" rid="B96">96</xref>,<xref ref-type="bibr" rid="B97">97</xref>]. It was first suggested in 1995 that soluble A&#x003b2; species rather than
fibrillar plaques could trigger neurotoxicity leading to AD [<xref ref-type="bibr" rid="B98">98</xref>], and in the subsequent decades, many studies have shown soluble A&#x003b2;
oligomers to be the most toxic A&#x003b2; form, causing both acute synaptotoxicity and
inducing neurodegenerative processes [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B99">99</xref>-<xref ref-type="bibr" rid="B102">102</xref>].</p><p>Low-picomolar levels of soluble A&#x003b2; oligomers have been reported to have trophic
properties <italic>in vitro</italic>[<xref ref-type="bibr" rid="B103">103</xref>-<xref ref-type="bibr" rid="B105">105</xref>], suggesting that therapeutic targeting of soluble A&#x003b2; oligomers may need
to modulate oligomer levels versus completely sequestering or preventing formation of
soluble A&#x003b2; oligomers. However, the concentration of A&#x003b2;42 at which enhancement
of long-term potentiation (LTP) was observed in these studies was one to two orders of
magnitude greater than levels of soluble A&#x003b2; oligomers reported in the cerebrospinal
fluid (CSF) of human patients with AD, and the concentration above which inhibition of
LTP was observed was an order of magnitude greater than the total levels of soluble
A&#x003b2; species reported in the CSF of human patients with AD [<xref ref-type="bibr" rid="B65">65</xref>]. Thus, the relevance of the reported <italic>in vitro</italic> trophic properties of
soluble A&#x003b2; oligomers to <italic>in vivo</italic> conditions remains to be established.</p><p>Soluble A&#x003b2; oligomers bind with high affinity to synapses on a subset of hippocampal
and cortical neurons [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B106">106</xref>-<xref ref-type="bibr" rid="B108">108</xref>], indicative of specific binding to discrete cell surface receptors. In rodent
hippocampal slice preparations, synaptic binding leads to rapid inhibition of LTP [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B109">109</xref>], and injection of various soluble A&#x003b2; oligomer preparations directly into
the rodent brain leads to reversible impairment of cognitive function [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B110">110</xref>]. This aberrant signaling also causes accumulated biochemical damage within
neurons [<xref ref-type="bibr" rid="B100">100</xref>,<xref ref-type="bibr" rid="B111">111</xref>,<xref ref-type="bibr" rid="B112">112</xref>], such as hyperphosphorylation of tau [<xref ref-type="bibr" rid="B100">100</xref>,<xref ref-type="bibr" rid="B111">111</xref>-<xref ref-type="bibr" rid="B113">113</xref>], suggesting a linkage between A&#x003b2; and tau pathologies [<xref ref-type="bibr" rid="B114">114</xref>-<xref ref-type="bibr" rid="B116">116</xref>]. Soluble A&#x003b2; oligomers have been isolated from extracts of postmortem AD
brain tissue and from transgenic AD animal models [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B117">117</xref>-<xref ref-type="bibr" rid="B119">119</xref>] and have been reported to be elevated in human AD brain relative to
non-demented older patients [<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B61">61</xref>,<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B119">119</xref>-<xref ref-type="bibr" rid="B124">124</xref>]. Importantly, a recent study suggests a correlation between CSF levels of
soluble A&#x003b2; oligomers and cognitive deficits in human patients with AD [<xref ref-type="bibr" rid="B61">61</xref>,<xref ref-type="bibr" rid="B65">65</xref>]. These findings support the view that soluble A&#x003b2; oligomers interfere
acutely with normal synaptic functions and contribute significantly to the memory loss
and cognitive dysfunction characteristic of AD.</p></sec><sec><title>Structure and activity of soluble amyloid-beta oligomer species</title><p>There is substantial ongoing debate and research concerning the structure and activity
of soluble A&#x003b2; species [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B99">99</xref>,<xref ref-type="bibr" rid="B125">125</xref>-<xref ref-type="bibr" rid="B127">127</xref>]. Various soluble A&#x003b2; oligomer species have been reported to display
synaptic toxicity or induce cognitive deficits, including dimers [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B128">128</xref>,<xref ref-type="bibr" rid="B129">129</xref>], trimers [<xref ref-type="bibr" rid="B32">32</xref>], dodecamers [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B40">40</xref>], and larger soluble A&#x003b2; oligomers with molecular weights of 90 to 650 kDa
(20 to 150 mers) [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B130">130</xref>,<xref ref-type="bibr" rid="B131">131</xref>]. Unfortunately, the different methodologies for the preparation,
characterization, and evaluation of soluble A&#x003b2; oligomer species by various research
groups impede a direct comparison of the results reported, and few studies have directly
compared the toxicities of different soluble A&#x003b2; species while using the same
techniques.</p><p>Two studies have reported the comparative toxicities of different soluble A&#x003b2;
oligomer species by using LDH (lactate dehydrogenase release) and MTT (oxidoreductase
activity) cell viability assays. Deshpande and colleagues [<xref ref-type="bibr" rid="B45">45</xref>] examined the relative toxicities of purified spherical A&#x003b2;(1-42)
oligomers [<xref ref-type="bibr" rid="B50">50</xref>], ADDLs [<xref ref-type="bibr" rid="B132">132</xref>], and fibrils [<xref ref-type="bibr" rid="B50">50</xref>]. However, because solutions of soluble A&#x003b2; oligomers in the neurobasal
medium used in this study have been shown to change with time [<xref ref-type="bibr" rid="B19">19</xref>], it is not possible to draw definitive structure-activity conclusions from
the results of this study. In the second study, Ono and colleagues [<xref ref-type="bibr" rid="B133">133</xref>] reported relative toxicities of purified, cross-linked A&#x003b2;(1-40) dimers,
trimers, and tetramers, which were shown to be relatively stable under the assay
conditions. In an MTT assay, half maximal effective concentration values were 67.3,
41.6, 24.5, 20.5, and 57.6 &#x003bc;M, respectively, for monomer, dimer, trimer, tetramer,
and fibrils. Comparable toxicity was obtained in an LDH assay. The micromolar
concentrations of A&#x003b2; species used in this study were approximately six orders of
magnitude greater than <italic>in vivo</italic> A&#x003b2; concentrations, and the relevance of
cell culture MTT-type assays to the <italic>in vivo</italic> synaptotoxicity of A&#x003b2; species
has been questioned [<xref ref-type="bibr" rid="B134">134</xref>]. Therefore, the results of the study by Ono and colleagues provide little
understanding of the relative <italic>in vivo</italic> toxicities of soluble A&#x003b2;
species.</p><p>More recently, cognitive effects <italic>in vivo</italic> were assessed in rats by using the
alternating lever cyclic ratio assay following intracerebroventricular (ICV) injections
of cell- and synthetically derived soluble A&#x003b2; oligomers [<xref ref-type="bibr" rid="B33">33</xref>]. Monomer and low-n-mer soluble A&#x003b2; oligomers derived from 7PA2 cells [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B135">135</xref>-<xref ref-type="bibr" rid="B137">137</xref>], trimer and a dodecameric species (A&#x003b2;*56) extracted from Tg2576 mouse
brain [<xref ref-type="bibr" rid="B37">37</xref>], and synthetic soluble A&#x003b2; oligomers (ADDLs) [<xref ref-type="bibr" rid="B43">43</xref>] were compared in this study. Injection of conditioned media from 7PA2 cells
caused significant cognitive deficits. Evaluation of size exclusion chromatography
(SEC)-enriched dimer or trimer fractions of 7PA2 cell-conditioned media showed
significant cognitive deficits following injection of dimer-enriched fractions but a
non-significant effect upon injection of trimer-enriched fractions. SEC-purified monomer
had no effect. A&#x003b2; monomer was the predominant A&#x003b2; species in unfractionated
7PA2 conditioned media, and the amounts of dimer and trimer injected in the dimer- and
trimer-enriched fractions were considerably greater than the amounts injected in
unfractionated conditioned media. However, cognitive effects following injection of
unfractionated conditioned media were comparable to or exceeded the observed effects
following treatment with dimer- and trimer-enriched fractions. Thus, there is an
inherent ambiguity regarding the results reported for 7PA2-derived A&#x003b2; species that
is difficult to explain. One possible explanation is that a higher-order soluble A&#x003b2;
oligomer species contributes to the cognitive deficits observed upon injection of
unfractionated 7PA2 conditioned media and is a more potent inhibitor of cognitive
function than A&#x003b2; dimer or trimer species or both. Another possible explanation is
that combinations of different soluble A&#x003b2; oligomer species, perhaps interacting
differently with different neuronal receptors, have an additive or synergistic
toxicological effect. Trimers extracted from aged Tg2576 mouse brain also failed to
elicit significant cognitive deficits. However, consistent with other <italic>in vivo</italic>
efficacy studies [<xref ref-type="bibr" rid="B37">37</xref>], a dodecameric soluble A&#x003b2; oligomer extracted from aged Tg2576 mouse
brain (A&#x003b2;*56) caused significant cognitive deficits. Synthetic soluble A&#x003b2;
oligomers (ADDLs) also caused cognitive deficits following ICV injection. The results of
this study show that ICV injection of soluble A&#x003b2; oligomers from different sources
causes cognitive deficits in wild-type rats and that these deficits are reversible. The
results of the study show that soluble A&#x003b2; oligomer containing conditioned media of
7PA2 cells is more potent than solutions of A&#x003b2;*56 obtained from aged Tg2576 mouse
brains or solutions of synthetically prepared soluble A&#x003b2; oligomers (ADDLs).
However, because it is not possible to quantitatively characterize the exact nature or
distribution of soluble A&#x003b2; species in these different preparations, it is not
possible to draw definitive conclusions from this study regarding the structure-activity
relationships between individual soluble A&#x003b2; oligomer species.</p><p>In a more recent study, Moreth and colleagues [<xref ref-type="bibr" rid="B19">19</xref>] prepared, characterized, and evaluated the hippocampal binding and effects on
neurotransmission of spheroidal, protofibrillar, and fibrillar A&#x003b2; aggregates. Under
the conditions used to test for hippocampal binding and neurotransmission, the different
species where shown to be relatively unchanged. Monomeric and fibrillar A&#x003b2; did not
bind to mature hippocampal neurons (DIV21) or effect neurotransmission at concentrations
as high as 1 &#x003bc;M. In contrast, spheroidal and protofibrillar A&#x003b2; aggregates
displayed punctate binding to mature hippocampal neurons and impaired neurotransmission
with nanomolar potency. Significantly, the mode of impairment of neurotransmission was
different for spheroidal A&#x003b2; aggregates, which impaired LTP at 30 nM, compared with
protofibrillar aggregates, which impaired basal neurotransmission at 100 nM. Spheroidal
A&#x003b2; aggregates had no effect on basal neurotransmission at concentrations as high as
100 nM. Although this study was unable to address the comparative neurotoxicity of
discrete soluble A&#x003b2; oligomers, it did show that different forms of soluble A&#x003b2;
oligomers can trigger distinct neuronal activities.</p><p>At this point, the exact structures of the toxicologically relevant soluble A&#x003b2;
oligomer species have not been determined to the complete exclusion of other possible
structures, and analytical tools do not exist to characterize the A&#x003b2; oligomers that
form at concentrations in the AD brain [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B138">138</xref>]. The numerous studies reporting neuronal toxicity for different soluble
A&#x003b2; oligomers support the conclusion that multiple soluble A&#x003b2; oligomer species
exhibit neuronal toxicity, rather than a single, discrete toxic species. This suggestion
of multiple toxic soluble A&#x003b2; oligomer species may also explain the plethora of
reported neuronal receptors that mediate the effects of soluble A&#x003b2; oligomers
(Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>) [<xref ref-type="bibr" rid="B139">139</xref>-<xref ref-type="bibr" rid="B165">165</xref>], a discussion of which is well beyond the scope of this review. (See the
perspective of Benilova and De Strooper [<xref ref-type="bibr" rid="B166">166</xref>] for a good introduction to this complex and controversial field of
study.)</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Reported receptors that bind or mediate the toxicity of soluble amyloid-beta
oligomers</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th colspan="3" align="left"><bold>Reported receptor</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Amylin receptor [<xref ref-type="bibr" rid="B139">139</xref>]<hr/></td><td align="left" valign="bottom">NMDA receptor [<xref ref-type="bibr" rid="B140">140</xref>-<xref ref-type="bibr" rid="B144">144</xref>]<hr/></td><td align="left" valign="bottom">Sortilin [<xref ref-type="bibr" rid="B145">145</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">P53-Bax cell death pathway [<xref ref-type="bibr" rid="B146">146</xref>]<hr/></td><td align="left" valign="bottom">cAMP/PKA/CREB-signaling pathway [<xref ref-type="bibr" rid="B147">147</xref>,<xref ref-type="bibr" rid="B148">148</xref>]<hr/></td><td align="left" valign="bottom">Tau protein kinase 1/glycogen synthase kinase-3&#x003b2; [<xref ref-type="bibr" rid="B51">51</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">c-Jun N-terminal kinase [<xref ref-type="bibr" rid="B149">149</xref>]<hr/></td><td align="left" valign="bottom">&#x003b1;-synuclein [<xref ref-type="bibr" rid="B150">150</xref>]<hr/></td><td align="left" valign="bottom">P/Q-type calcium currents [<xref ref-type="bibr" rid="B49">49</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">Cyclin-dependent kinase 5 [<xref ref-type="bibr" rid="B149">149</xref>]<hr/></td><td align="left" valign="bottom">EphB2 [<xref ref-type="bibr" rid="B151">151</xref>]<hr/></td><td align="left" valign="bottom">Dynamin and RhoA [<xref ref-type="bibr" rid="B152">152</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">mGluR, mGluR5, mGluR2 [<xref ref-type="bibr" rid="B108">108</xref>,<xref ref-type="bibr" rid="B142">142</xref>,<xref ref-type="bibr" rid="B149">149</xref>,<xref ref-type="bibr" rid="B153">153</xref>,<xref ref-type="bibr" rid="B154">154</xref>]<hr/></td><td align="left" valign="bottom">TNF&#x003b1; [<xref ref-type="bibr" rid="B155">155</xref>]<hr/></td><td align="left" valign="bottom">Cofilin [<xref ref-type="bibr" rid="B140">140</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">p38 mitogen-activated protein kinase [<xref ref-type="bibr" rid="B149">149</xref>]<hr/></td><td align="left" valign="bottom">PrP<sup>c</sup>[<xref ref-type="bibr" rid="B154">154</xref>,<xref ref-type="bibr" rid="B156">156</xref>-<xref ref-type="bibr" rid="B159">159</xref>]<hr/></td><td align="left" valign="bottom">Calcineurin [<xref ref-type="bibr" rid="B160">160</xref>-<xref ref-type="bibr" rid="B162">162</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">&#x003b1; 7-nicotinic receptors [<xref ref-type="bibr" rid="B105">105</xref>]<hr/></td><td align="left" valign="bottom">AMPA [<xref ref-type="bibr" rid="B160">160</xref>]<hr/></td><td align="left" valign="bottom">Brain-derived neurotrophic factor [<xref ref-type="bibr" rid="B131">131</xref>]<hr/></td></tr><tr><td align="left" valign="bottom">Human LilrB2 [<xref ref-type="bibr" rid="B163">163</xref>]<hr/></td><td align="left" valign="bottom">Insulin receptor [<xref ref-type="bibr" rid="B164">164</xref>]<hr/></td><td align="left" valign="bottom">Sigma 2 receptor [<xref ref-type="bibr" rid="B165">165</xref>]<hr/></td></tr><tr><td align="left">STI1 [<xref ref-type="bibr" rid="B156">156</xref>]</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>NMDA, N-methyl-D-aspartate; TNF&#x003b1;, tumor necrosis factor alpha.</p></table-wrap-foot></table-wrap><p>Despite recognition that soluble A&#x003b2; oligomers are key structures causing AD memory
malfunction and cognitive deficits, drug discovery efforts targeting these species have
been hampered by perceived technical difficulties of generating physiologically relevant
preparations of synthetic soluble A&#x003b2; oligomers and by differing terminologies and
methodologies used by various researchers [<xref ref-type="bibr" rid="B167">167</xref>]. However, well-characterized and documented preparations of synthetic soluble
A&#x003b2; oligomers have been reported by numerous researchers [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B95">95</xref>,<xref ref-type="bibr" rid="B100">100</xref>,<xref ref-type="bibr" rid="B107">107</xref>,<xref ref-type="bibr" rid="B108">108</xref>,<xref ref-type="bibr" rid="B111">111</xref>,<xref ref-type="bibr" rid="B168">168</xref>-<xref ref-type="bibr" rid="B170">170</xref>] that generate soluble A&#x003b2; oligomers with little or no detectable
fibrillar A&#x003b2; species. With the availability of a number of well-documented
preparations of different soluble A&#x003b2; oligomer species and tools for comparative
characterization, it is hoped that additional side-by-side testing of various soluble
A&#x003b2; oligomer preparations in different toxicity paradigms such as reversal of basal
neurotransmission, LTP inhibition, changes in AMPA receptor trafficking, tau
phosphorylation, and loss of dendritic spines [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B108">108</xref>,<xref ref-type="bibr" rid="B109">109</xref>,<xref ref-type="bibr" rid="B170">170</xref>] will be conducted and reported.</p></sec><sec><title>Amyloid-beta immunotherapies in development</title><p>Successful immunotherapies developed for most diseases rely upon antibodies that possess
high selectivity for a particular target antigen connected to the disease. However, all
A&#x003b2;-directed immunotherapies currently in clinical development are based on
non-selective antibodies that bind multiple A&#x003b2; species. Treatment with
non-selective anti-A&#x003b2; antibodies that bind monomeric or oligomeric A&#x003b2; (or
both) potentially could succeed in a prodromal treatment paradigm by reducing total
brain A&#x003b2; to levels below the toxicological threshold. However, given the high
concentrations of monomeric and fibrillar A&#x003b2; compared with soluble A&#x003b2;
oligomers in the AD brain [<xref ref-type="bibr" rid="B57">57</xref>-<xref ref-type="bibr" rid="B65">65</xref>] and the low levels of antibodies that penetrate the brain from the periphery [<xref ref-type="bibr" rid="B171">171</xref>], it will be very challenging for non-selective anti-A&#x003b2; antibodies that
bind monomeric or fibrillar A&#x003b2; (or both) to show efficacy when administered to
patients with mild cognitive impairment or mild-to-moderate AD. In contrast, the acute
synaptic toxicity and very low brain levels of soluble A&#x003b2; oligomers suggest that
anti-A&#x003b2; antibodies with selective affinity for soluble A&#x003b2; oligomers could
provide therapeutic benefit for patients with mild cognitive impairment or
mild-to-moderate AD.</p><p>It might seem difficult to generate a monoclonal antibody that does not bind monomeric
or fibrillar A&#x003b2; yet possesses high affinity for structurally heterogeneous soluble
A&#x003b2; oligomers. However, monomeric, oligomeric, and fibrillar A&#x003b2; species have
been reported to have distinct conformational characteristics [<xref ref-type="bibr" rid="B172">172</xref>-<xref ref-type="bibr" rid="B175">175</xref>]. Moreover, antibodies with selective affinity for soluble A&#x003b2; oligomers
versus monomeric and fibrillar A&#x003b2; have been reported [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B176">176</xref>,<xref ref-type="bibr" rid="B177">177</xref>]. These several examples of antibodies suggest that therapeutically relevant
soluble A&#x003b2; oligomer-directed antibodies are indeed feasible.</p><p>A number of recent publications have reviewed A&#x003b2; immunotherapies currently in
clinical trials, with an emphasis on the efficacy of the drugs for treating AD [<xref ref-type="bibr" rid="B178">178</xref>-<xref ref-type="bibr" rid="B187">187</xref>], and the clinical results will not be presented in this review, with the
exception of an analysis of the brain levels of solanezumab and bapineuzumab in recently
reported clinical trials. Instead, this review will focus on a discussion of the
comparative affinities of the A&#x003b2; antibodies in clinical development for monomeric,
soluble oligomeric, and fibrillar A&#x003b2; species. Notably, none of the A&#x003b2;
immunotherapies currently in clinical development selectively targets soluble A&#x003b2;
oligomers, as discussed below and summarized in Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Comparison of binding affinities of amyloid-beta (A&#x003b2;) immunotherapies in
development for A&#x003b2; monomer, soluble A&#x003b2; oligomers, and fibrillar
A&#x003b2;</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="3" align="center" valign="bottom"><bold>Binding affinity</bold><sup>
<bold>a</bold>
</sup><hr/></th></tr><tr><th align="left"><bold>A&#x003b2; antibody</bold></th><th align="center"><bold>A&#x003b2; monomer</bold></th><th align="center"><bold>A&#x003b2; oligomers</bold></th><th align="center"><bold>A&#x003b2; plaque</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Solanezumab/266<hr/></td><td align="center" valign="bottom">+++<hr/></td><td align="center" valign="bottom">++<hr/></td><td align="center" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom">Bapineuzumab/3D6<hr/></td><td align="center" valign="bottom">++<hr/></td><td align="center" valign="bottom">+++<hr/></td><td align="center" valign="bottom">+++<hr/></td></tr><tr><td align="left" valign="bottom">Crenezumab<hr/></td><td align="center" valign="bottom">++<hr/></td><td align="center" valign="bottom">+++<hr/></td><td align="center" valign="bottom">++<hr/></td></tr><tr><td align="left" valign="bottom">Ponezumab/D-2H6<hr/></td><td align="center" valign="bottom">++<hr/></td><td align="center" valign="bottom">++<hr/></td><td align="center" valign="bottom">+++<hr/></td></tr><tr><td align="left" valign="bottom">BiiB037/NI-101.11<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+++<hr/></td><td align="center" valign="bottom">+++<hr/></td></tr><tr><td align="left" valign="bottom">BAN2401/mAb158<hr/></td><td align="center" valign="bottom">-<hr/></td><td align="center" valign="bottom">+++<hr/></td><td align="center" valign="bottom">+++<hr/></td></tr><tr><td align="left" valign="bottom">Gantenerumab<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">++<hr/></td><td align="center" valign="bottom">+++<hr/></td></tr><tr><td align="left">SAR228810/13C3</td><td align="center">-</td><td align="center">+++</td><td align="center">+++</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Based on published patent applications or peer-reviewed scientific
publications. +, low affinity binding; ++, moderate affinity binding; +++, high
affinity binding; -, very low affinity or no binding.</p></table-wrap-foot></table-wrap><sec><title>Solanezumab</title><p>Solanezumab is unique among A&#x003b2; antibodies currently in clinical development
because it does not bind fibrillar A&#x003b2;. Solanezumab is a humanized, IgG1
monoclonal antibody derived from the murine monoclonal antibody, 266. 266 was
selected for its high-affinity binding to soluble A&#x003b2;, although the exact nature
of the soluble A&#x003b2; it binds was not reported. It has been suggested that 266 is a
conformation-specific antibody that solely recognizes soluble A&#x003b2; and readily
binds monomeric A&#x003b2; [<xref ref-type="bibr" rid="B188">188</xref>-<xref ref-type="bibr" rid="B190">190</xref>], without binding APP or the C-terminal APP cleavage product of
&#x003b1;-secretase [<xref ref-type="bibr" rid="B189">189</xref>]. It has been reported that 266 selectively sequesters A&#x003b2; monomer and
dimer in the periphery of 3-month-old APP transgenic mice [<xref ref-type="bibr" rid="B190">190</xref>], and definitive evidence for 266 binding of monomeric A&#x003b2; has been
reported [<xref ref-type="bibr" rid="B191">191</xref>]. A study using crossed-linked soluble A&#x003b2; oligomers showed 266 could
immunoprecipate A&#x003b2; monomer and low-molecular-weight dimer, trimer, and possibly
tetramer [<xref ref-type="bibr" rid="B192">192</xref>]. A study involving a competitive ELISA showed that 266 had a seven-fold
higher affinity for monomeric A&#x003b2; than synthetic soluble A&#x003b2; oligomers [<xref ref-type="bibr" rid="B193">193</xref>]. Several studies have shown that 266 does not bind A&#x003b2; plaques or
vascular amyloid [<xref ref-type="bibr" rid="B188">188</xref>,<xref ref-type="bibr" rid="B190">190</xref>,<xref ref-type="bibr" rid="B194">194</xref>]. Thus, according to the available data, solanezumab and 266 bind monomeric
and lower-molecular-weight soluble A&#x003b2; oligomer species, with a preference for
monomeric A&#x003b2;, but do not bind fibrillar A&#x003b2; species.</p><p>Clinical trial pharmacokinetic data for brain levels of solanezumab have not been
reported. However, target engagement data reported for the phase 2, multiple
ascending-dose clinical trials (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>) [<xref ref-type="bibr" rid="B183">183</xref>] provide a possible understanding of the lack of efficacy of solanezumab in
clinical trials [<xref ref-type="bibr" rid="B186">186</xref>]. The data for the 400 mg/month and 400 mg/week dose levels show
approximately a 2.7-fold increase in solanezumab bound A&#x003b2; at the higher dose
level (5,858 versus 15,825 pg/mL total A&#x003b2;40 and A&#x003b2;42) [<xref ref-type="bibr" rid="B183">183</xref>], showing that there was incomplete target engagement at the 400 mg/month
dose level used in the pivotal phase 3 trials. Solanezumab binds A&#x003b2; monomer with
higher affinity than soluble A&#x003b2; oligomers and does not bind or disaggregate
fibrillar A&#x003b2;. Because incomplete target engagement occurred at the dose level
used in the phase 3 trials, it is unlikely any solanezumab was available to bind
soluble A&#x003b2; oligomers; thus, the lack of efficacy of solanezumab at the dose
levels used in the phase 3 clinical trials is not unexpected.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Mean cerebrospinal fluid levels of bound and unbound amyloid-beta
(A&#x003b2;)40 and A&#x003b2;42 in Alzheimer&#x02019;s disease patients treated with
solanezumab</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Solanezumab dose</bold><sup>
<bold>a</bold>
</sup></th><th align="center"><bold>Mean CSF A&#x003b2;40, pg/mL</bold><sup>
<bold>b</bold>
</sup></th><th align="center"><bold>Mean CSF A&#x003b2;42, pg/mL</bold><sup>
<bold>b</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">100 mg Q4W<hr/></td><td align="center" valign="bottom">625<hr/></td><td align="center" valign="bottom">0.0<hr/></td></tr><tr><td align="left" valign="bottom">100 mg QW<hr/></td><td align="center" valign="bottom">3,750<hr/></td><td align="center" valign="bottom">275<hr/></td></tr><tr><td align="left" valign="bottom">400 mg Q4W<hr/></td><td align="center" valign="bottom">5,625<hr/></td><td align="center" valign="bottom">233<hr/></td></tr><tr><td align="left">400 mg QW</td><td align="center">15,000</td><td align="center">825</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Solanezumab phase 2 MAD data [<xref ref-type="bibr" rid="B183">183</xref>]. <sup>b</sup>Mean pg/mL levels of total bound and unbound
A&#x003b2;40 and A&#x003b2;42 in cerebrospinal fluid (CSF) of treated patients,
derived from Figures 3A and 3B reported by Farlow and colleagues [<xref ref-type="bibr" rid="B183">183</xref>]. Q4W, monthly dosing; QW, weekly dosing.</p></table-wrap-foot></table-wrap></sec><sec><title>Bapineuzumab</title><p>Bapineuzumab is a humanized, IgG1 monoclonal antibody derived from the murine
antibody, 3D6. Bapineuzumab and 3D6 are non-selective A&#x003b2; antibodies that bind
with high affinity to monomeric A&#x003b2; [<xref ref-type="bibr" rid="B192">192</xref>], soluble A&#x003b2; oligomers [<xref ref-type="bibr" rid="B170">170</xref>], and fibrillar A&#x003b2; [<xref ref-type="bibr" rid="B195">195</xref>-<xref ref-type="bibr" rid="B197">197</xref>] but do not recognize APP or the product of &#x003b2;-secretase cleavage of
APP [<xref ref-type="bibr" rid="B198">198</xref>]. In a competitive ELISA assay study, 3D6 was found to bind monomeric
A&#x003b2; and synthetic soluble A&#x003b2; oligomers with similar affinity [<xref ref-type="bibr" rid="B193">193</xref>]. Babineuzumab/3D6 bind vascular amyloid and A&#x003b2; plaques in hAPP
transgenic mice brains and human AD brains and clear vascular amyloid and A&#x003b2;
plaques in hAPP transgenic mice brains [<xref ref-type="bibr" rid="B188">188</xref>,<xref ref-type="bibr" rid="B197">197</xref>,<xref ref-type="bibr" rid="B199">199</xref>-<xref ref-type="bibr" rid="B201">201</xref>]. Thus, bapineuzumab and 3D6 do not distinguish between the various A&#x003b2;
species in the AD brain.</p><p>Mean CSF levels of bapineuzumab reported in the phase 2, multiple ascending-dose
pharmacokinetic clinical studies were 4.9, 18.1, 27.2, and 44.7 ng/mL, respectively,
at dose levels of 0.15, 0.5, 1.0, and 2 mg/kg (six infusions, 13 weeks apart) [<xref ref-type="bibr" rid="B202">202</xref>], which upon conversion to molar concentrations are 0.03, 0.12, 0.18, and
0.3 pmol/mL, respectively, based on a bapineuzumab molecular weight of 150 kDa. In
the same studies, placebo-treated mean CSF levels of A&#x003b2;(1-42), A&#x003b2;(x-42),
and A&#x003b2;(1-40) were 376.7, 537.9, and 6,705.4 pg/mL, respectively, which upon
conversion to molar concentrations are 0.08, 0.12, and 1.55 pmol/mL, respectively
(assuming the molecular weight of A&#x003b2;(x-42) is the same as that of
A&#x003b2;(1-40)). The highest bapineuzumab dose level in phase 3 pivotal trials was 1
mg/kg (six infusions, once every 13 weeks) [<xref ref-type="bibr" rid="B187">187</xref>]. Thus, the total mean A&#x003b2; CSF levels were approximately an order of
magnitude greater than mean levels of bapineuzumab. Because bapineuzumab binds
monomeric A&#x003b2; with similar affinity to soluble A&#x003b2; oligomers and fibrillar
A&#x003b2; and because A&#x003b2; soluble oligomer levels are orders of magnitude less than
A&#x003b2; monomer and fibrils levels in the AD brain [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B65">65</xref>], it is clear that bapineuzumab was not dosed high enough in the pivotal
phase 3 trials to effectively sequester soluble A&#x003b2; oligomers. Thus, the absence
of efficacy of bapineuzumab in clinical trials is not unexpected.</p></sec><sec><title>Crenezumab</title><p>Crenezumab (MABT5102A or MABT) is a humanized, IgG4 monoclonal anti-A&#x003b2; antibody
that was engineered to reduce Fc&#x003b3; receptor-mediated microglia activation and
minimize adverse effects due to vasogenic edema and cerebral microhemorrhage [<xref ref-type="bibr" rid="B203">203</xref>,<xref ref-type="bibr" rid="B204">204</xref>]. Crenezumab binds A&#x003b2; monomer, soluble A&#x003b2; oligomers, and
fibrillar A&#x003b2; with similar affinities and binds plaques in hAPP transgenic mice
and human AD brain tissues [<xref ref-type="bibr" rid="B203">203</xref>,<xref ref-type="bibr" rid="B204">204</xref>]. Similar binding of crenezumab to human A&#x003b2;(1-40) and A&#x003b2;(1-42)
peptides and mouse/rat A&#x003b2;(1-42) has also been reported [<xref ref-type="bibr" rid="B204">204</xref>]. These results indicate that crenezumab does not possess selectivity for
different A&#x003b2; species [<xref ref-type="bibr" rid="B204">204</xref>]. Consistent with a lack of selectivity, crenezumab prevents A&#x003b2;
aggregation and disaggregates pre-aggregated A&#x003b2; species. Thus, crenezumab is
similar to bapineuzumab with respect to non-selective binding of monomeric,
oligomeric, and fibrillar A&#x003b2; species.</p></sec><sec><title>Ponezumab</title><p>Ponezumab is a humanized, modified IgG2 monoclonal antibody derived from the murine
monoclonal antibody, 2H6. This progenitor murine antibody binds to monomeric
A&#x003b2;(1-40) with high affinity but does not bind to A&#x003b2;(1-16), A&#x003b2;(1-28),
A&#x003b2;(1-38), A&#x003b2;(1-42), or A&#x003b2;(1-43) [<xref ref-type="bibr" rid="B205">205</xref>]. Intracranial injection of 2H6 and its deglycosylated form into
plaque-rich, 20-month-old Tg2576 mice followed by histological analysis of total
A&#x003b2; load in the hippocampus and frontal cortex showed significant plaque
reduction in both regions compared with control tissues [<xref ref-type="bibr" rid="B206">206</xref>], suggesting that these antibodies bind and disaggregate fibrillar amyloid.
More recent studies show that ponezumab labels amyloid plaques in 14-month-old Tg2576
mouse and human AD brains [<xref ref-type="bibr" rid="B207">207</xref>], demonstrating binding to fibrillar A&#x003b2;. Binding of ponezumab to
Tg2576 mouse brain plaque was comparable to the known high-affinity binding of the
N-terminal A&#x003b2; antibody 6E10. Ponezumab was also reported to bind monomeric,
oligomeric, and fibrillar forms of A&#x003b2;(1-40) but did not show appreciable binding
to monomeric, oligomeric, or fibrillar forms of A&#x003b2;(1-42) [<xref ref-type="bibr" rid="B207">207</xref>]. Thus, although ponezumab displays selectivity for A&#x003b2;(1-40) versus
other A&#x003b2; peptide isoforms, it is relatively non-selective for monomeric, soluble
oligomeric, or fibrillar A&#x003b2; species.</p></sec><sec><title>BiiB037</title><p>BiiB037 is a human IgG1 monoclonal antibody derived from a patient with AD by using
reverse translational medicine methodology [<xref ref-type="bibr" rid="B208">208</xref>]. <italic>In vitro</italic> BiiB037 binds fibrillar A&#x003b2;(1-42) with high
affinity but does not bind soluble A&#x003b2;(1-40) [<xref ref-type="bibr" rid="B209">209</xref>]. Although explicit details of the binding characteristics of BiiB037 have
not been publicly disclosed, results reported by Dunstan and colleagues [<xref ref-type="bibr" rid="B209">209</xref>] and data in the patent covering BiiB037 [<xref ref-type="bibr" rid="B208">208</xref>] suggest that BiiB037 is very similar, or identical, to antibody NI-101.11,
which binds with high affinity to A&#x003b2; plaques in human AD brain tissue samples [<xref ref-type="bibr" rid="B208">208</xref>]. Such binding is not blocked by monomeric A&#x003b2;(1-16) or A&#x003b2;(1-42),
showing selective affinity for fibrillar A&#x003b2; versus A&#x003b2; monomers [<xref ref-type="bibr" rid="B208">208</xref>]. Comparison of binding affinity in an A&#x003b2; plate-based ELISA showed
greater than 100-fold-higher affinity for fibrillar A&#x003b2;(1-42) than for monomeric
A&#x003b2;(1-42) [<xref ref-type="bibr" rid="B208">208</xref>]. SEC studies showed that NI-101.11 bound to fluorescein
isothiocyanate-labeled A&#x003b2;(1-42) in the early-eluting peak (non-retained, large
A&#x003b2; species) but that little binding was associated with the retained,
low-molecular-weight A&#x003b2; peak [<xref ref-type="bibr" rid="B208">208</xref>]. Many researchers have deployed SEC to separate higher-molecular-weight
soluble A&#x003b2; oligomer species from low-molecular-weight A&#x003b2; species [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B130">130</xref>,<xref ref-type="bibr" rid="B155">155</xref>,<xref ref-type="bibr" rid="B210">210</xref>-<xref ref-type="bibr" rid="B212">212</xref>], and in all cases the higher-molecular-weight, early-eluting peak contains
soluble A&#x003b2; oligomers or A&#x003b2; protofibrils or both. Together these results
show that NI-101.11 binds soluble A&#x003b2; oligomers and protofibrils in addition to
fibrillar A&#x003b2;. Consistent with this conclusion is the finding that NI-101.11
inhibits the formation of A&#x003b2; fibrils <italic>in vitro</italic>[<xref ref-type="bibr" rid="B208">208</xref>]. Thus, according to the available data, BiiB037/NI-101.11 binds soluble
A&#x003b2; oligomers and fibrillar A&#x003b2; with high affinity and binds monomeric
A&#x003b2; with low affinity.</p></sec><sec><title>BAN2401</title><p>BAN2401 is a humanized, IgG2a monoclonal antibody derived from the murine precursor
mAb158, which was raised against A&#x003b2; protofibrils generated from
A&#x003b2;(1-42)-E22G, the arctic mutant of the A&#x003b2; peptide [<xref ref-type="bibr" rid="B210">210</xref>]. Although mAb158 is claimed to be a &#x02018;highly protofibril-selective
monoclonal antibody&#x02019; [<xref ref-type="bibr" rid="B213">213</xref>], published data show that it binds fibrillar A&#x003b2; with a high affinity
similar to that of protofibrils in a dot-blot assay [<xref ref-type="bibr" rid="B210">210</xref>,<xref ref-type="bibr" rid="B214">214</xref>] and binds fibrillar deposits in transgenic APP-ArcSwe mice brain (see
Figure S2 in [<xref ref-type="bibr" rid="B213">213</xref>]). In a more recent study, mAb158 was shown to bind soluble A&#x003b2;
oligomer fractions in the molecular weight range of 80 to 2,000 kDa under conditions
in which protofibrillar species were not detected [<xref ref-type="bibr" rid="B119">119</xref>]. In this study, mAb158 showed essentially no binding to
low-molecular-weight A&#x003b2; oligomeric species in the molecular weight range of 5 to
80 kDa. A lack of binding to low-molecular-weight A&#x003b2; species - monomeric to
tetrameric A&#x003b2;(1-40), A&#x003b2;(1-16), and A&#x003b2;(17-40) - was found in an earlier
study [<xref ref-type="bibr" rid="B213">213</xref>]. Thus, mAb158 binds higher-molecular-weight A&#x003b2; aggregates, including
soluble A&#x003b2; oligomers, protofibrils, and fibrillar A&#x003b2;. Consistent with the
binding of mAb158 to fibrillar A&#x003b2;, intracranial injection of mA&#x003b2;158 in a
transgenic APP-Swe mouse model was reported to cause a significant reduction in
plaque burden by 72 hours after injection [<xref ref-type="bibr" rid="B214">214</xref>]. In a subsequent study in a transgenic APP-ArcSwe mouse model [<xref ref-type="bibr" rid="B213">213</xref>], 4 months of weekly intraperitoneal injections of mAb158 to 9- to
10-month-old mice with modest plaque burden resulted in a significant reduction of
A&#x003b2; protofibrils (74%) but no significant reduction in total soluble or insoluble
A&#x003b2; levels in the cerebral cortex or hippocampus as determined by
immunohistochemical analysis. The differences in effects of mAb158 on existing plaque
burden in these two studies may be due to different administration routes (direct
intracranial versus peripheral injections). As noted by Lord and colleagues [<xref ref-type="bibr" rid="B213">213</xref>], it may also be attributable to the APP-ArcSwe mouse model used in the
more recent study, a model that exhibits more highly insoluble dense-core plaques,
preventable only by early and continuous A&#x003b2; immunotherapy. Thus, mAb158/BAN2401
binds higher-molecular-weight soluble A&#x003b2; oligomers (referred to as protofibrils
in the mAb158 literature) and fibrillar A&#x003b2; with high affinity and has low
affinity for binding monomeric A&#x003b2; and lower-molecular-weight soluble A&#x003b2;
oligomers.</p></sec><sec><title>Gantenerumab</title><p>Gantenerumab is a humanized monoclonal antibody that was optimized to have
high-affinity binding of fibrillar A&#x003b2; and shows high-affinity binding to diffuse
and dense-core plaques in human AD brain and APP transgenic mouse brain tissues [<xref ref-type="bibr" rid="B215">215</xref>]. Gantenerumab also binds soluble A&#x003b2; oligomers with high affinity and,
to a lesser extent, A&#x003b2; monomer. The reported binding constants (Kds) for
gantenerumab binding to fibrillar A&#x003b2;, soluble A&#x003b2; oligomers, and A&#x003b2;
monomer are 0.6, 1.2, and 17 nM, respectively [<xref ref-type="bibr" rid="B215">215</xref>]. The dissociation constants (kds) for gantenerumab-A&#x003b2; complexes were
reported to be 2.8&#x02009;&#x000d7;&#x02009;10<sup>-4</sup>,
4.9&#x02009;&#x000d7;&#x02009;10<sup>-4</sup>, and
1.2&#x02009;&#x000d7;&#x02009;10<sup>-2</sup>, respectively, for fibrillar A&#x003b2;, A&#x003b2;
oligomers, and A&#x003b2; monomer [<xref ref-type="bibr" rid="B215">215</xref>], suggesting a more rapid exchange of antibody-monomer complex compared
with antibody-fibril or oligomer complexes. The selective affinity of gantenerumab
for fibrillar A&#x003b2; and soluble A&#x003b2; oligomers suggests that it may be similar
to BiiB013/NI-101.11 and BAN2401/mAb158. Consistent with its high-affinity binding to
fibrillar A&#x003b2;, gantenerumab caused a significant, dose-dependent reduction in
amyloid plaques in human AD brain tissue [<xref ref-type="bibr" rid="B215">215</xref>]. Immunohistochemical analysis of PS2APP transgenic mice brain tissue 3
days after intravenous injection of gantenerumab showed dose-dependent binding to
amyloid plaques. Significantly, pharmacokinetic analysis in PS2APP transgenic mice
following a single intravenous bolus dose showed sustained binding of gantenerumab to
plaques in the brain for up to 9 weeks post-dosing, even though there was no
detectable antibody in the plasma beyond 3 weeks post-dosing [<xref ref-type="bibr" rid="B215">215</xref>]. In a chronic treatment study in 5- to 6-month-old PS2APP transgenic mice,
gantenerumab caused a significant reduction in pre-existing small plaques; however,
there was an increase in larger plaques [<xref ref-type="bibr" rid="B215">215</xref>]. These results suggest that gantenerumab causes a redistribution of
A&#x003b2; from small plaques to large plaques, possibly via disaggregation of smaller,
less mature plaques. Gantenerumab-mediated disaggregation of existing plaques is
consistent with the observations of vasogenic edema and microhemorrhage in human
patients with AD treated with gantenerumab in clinical trials [<xref ref-type="bibr" rid="B216">216</xref>]. Thus, gantenerumab non-selectively binds soluble A&#x003b2; oligomers and
fibrillar A&#x003b2; with similar high affinity in comparison with its lower-affinity
binding of monomeric A&#x003b2;.</p></sec><sec><title>SAR228810</title><p>SAR228810 is a humanized, monoclonal antibody derived from the murine monoclonal
antibody 13C3, which was raised to A&#x003b2; protofibrils derived from A&#x003b2;(1-42) [<xref ref-type="bibr" rid="B217">217</xref>,<xref ref-type="bibr" rid="B218">218</xref>]. The humanized antibody was engineered into an IgG4 framework to reduce
binding to Fc&#x003b3; and C1q receptors and decrease risks of amyloid-related imaging
abnormalities [<xref ref-type="bibr" rid="B219">219</xref>]. Although specific binding characteristics of SAR228810 have not been
publicly disclosed, results reported by Pradier and colleagues [<xref ref-type="bibr" rid="B219">219</xref>] and data in the patent application claiming humanized variants of 13C3 [<xref ref-type="bibr" rid="B220">220</xref>] suggest that SAR228810 is very similar, or identical, to antibody LP09027 [<xref ref-type="bibr" rid="B220">220</xref>]. Antibody 13C3 and its humanized variants are reported to bind with higher
affinity to SEC-separated protofibrillar A&#x003b2;(1-42) than to low-molecular-weight
A&#x003b2;(1-42) [<xref ref-type="bibr" rid="B217">217</xref>,<xref ref-type="bibr" rid="B218">218</xref>,<xref ref-type="bibr" rid="B220">220</xref>]. As noted previously, many researchers have used SEC to separate
higher-molecular-weight soluble A&#x003b2; oligomer species from low-molecular-weight
A&#x003b2; species [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B130">130</xref>,<xref ref-type="bibr" rid="B155">155</xref>,<xref ref-type="bibr" rid="B210">210</xref>-<xref ref-type="bibr" rid="B212">212</xref>], and in all cases the higher-molecular-weight, early-eluting peak contains
soluble A&#x003b2; oligomers or A&#x003b2; protofibrils or both. Moreover, as reported by
Hepler and colleagues [<xref ref-type="bibr" rid="B44">44</xref>], the lower-molecular-weight, late-eluting peak contains predominately
monomeric A&#x003b2;. Thus, these data show that 13C3 and its humanized variants
selectively bind A&#x003b2; oligomers or protofibrils (or both) compared with monomeric
A&#x003b2;. In competitive ELISA experiments, monomeric A&#x003b2;(1-28), A&#x003b2;(1-16), or
A&#x003b2;(25-35) does not prevent binding of humanized 13C3 to plates coated with
A&#x003b2;(1-42) [<xref ref-type="bibr" rid="B220">220</xref>]. Ravetch and Fukuyama [<xref ref-type="bibr" rid="B218">218</xref>] reported that 13C3 binds only to the higher-molecular-weight A&#x003b2;
species contained in the supernatants from 7PA2 cells, in contrast to the
non-selective A&#x003b2; antibody 4G8 that binds low-, medium-, and
higher-molecular-weight A&#x003b2; species. Collectively, these data show the
selectivity of 13C3 for higher-molecular-weight A&#x003b2; oligomers versus
lower-molecular-weight A&#x003b2; oligomers and monomer. Antibody 13C3 was shown to bind
fibrillar A&#x003b2;(1-42) and label A&#x003b2; deposits in human AD brain tissue samples [<xref ref-type="bibr" rid="B218">218</xref>]. Antibody LP09027 was shown to bind fibrillar A&#x003b2; <italic>in vitro</italic>
and to label AB deposits in brain sections from APP-PS1 mice [<xref ref-type="bibr" rid="B220">220</xref>]. Thus, the reported data suggest that 13C3/SAR228810 is very similar to
mAb158/BAN2401 and binds higher-molecular-weight soluble A&#x003b2; oligomers (referred
to as protofibrils in the 13C3/SAR228810 literature) and fibrillar A&#x003b2; with high
affinity and has low affinity for binding monomeric A&#x003b2; and
lower-molecular-weight soluble A&#x003b2; oligomers.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The lack of efficacy observed for A&#x003b2; immunotherapies in clinical development is not
unexpected given their lack of selectivity for soluble A&#x003b2; oligomers compared with
monomeric or fibrillar A&#x003b2; and given the tremendous quantities of monomeric or
fibrillar A&#x003b2; in the AD brain relative to soluble A&#x003b2; oligomers. A&#x003b2;
antibodies optimized to bind soluble A&#x003b2; oligomers selectively are much more likely
to succeed in AD clinical trials and should be aggressively pursued.</p><p>The prediction that immunotherapies targeting soluble A&#x003b2; oligomers will elicit
clinical benefit is supported by studies of human A&#x003b2; autoantibodies, of which only
a subset appears to be disease-protective (in particular, the subset that preferentially
recognizes A&#x003b2; oligomers) [<xref ref-type="bibr" rid="B221">221</xref>-<xref ref-type="bibr" rid="B223">223</xref>]. Thus, immunotherapeutics with high selectivity for soluble A&#x003b2;
oligomers, which resemble these protective auto-antibodies, are expected to deliver a
clinical advantage compared with the non-selective immunotherapies in clinical
development.</p><p>Studies have demonstrated that antibodies with selective affinity for soluble A&#x003b2;
oligomers can block soluble A&#x003b2; oligomer-mediated synaptotoxicity in cell cultures [<xref ref-type="bibr" rid="B108">108</xref>,<xref ref-type="bibr" rid="B224">224</xref>] and rapidly normalize memory deficits in transgenic AD mouse models [<xref ref-type="bibr" rid="B176">176</xref>]. These findings support the concept that antibodies with selective affinity
for soluble A&#x003b2; oligomers may be a more effective therapeutic strategy than
antibodies with high affinity for monomeric or fibrillar A&#x003b2; or both.</p></sec><sec><title>Abbreviations</title><p>AD: Alzheimer&#x02019;s disease; ADDL: Amyloid-derived diffusible ligand; APP: Amyloid
precursor protein; A&#x003b2;: Amyloid-beta; CSF: Cerebrospinal fluid; ELISA: Enzyme-linked
immunosorbent assay; ICV: Intracerebroventricular; LDH: Lactate dehydrogenase release;
LTP: Long-term potentiation; SDS: Sodium dodecyl sulfate; SEC: Size exclusion
chromatography; TBS: Tris-buffered saline.</p></sec><sec><title>Competing interests</title><p>All authors are employees or paid consultants of Acumen Pharmaceuticals, Inc. and own
stock or stock options of this company.</p></sec><sec><title>Authors&#x02019; contributions</title><p>All authors read and approved the final manuscript.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><article-title>Alzheimer&#x02019;s Disease International, World Alzheimer Report, 2010: The Global
Economic Impact of Dementia</article-title><source>Alzheimer&#x02019;s Disease International</source><year>2010</year><comment>[<ext-link ext-link-type="uri" xlink:href="http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf">http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf</ext-link>]</comment><pub-id pub-id-type="pmid">24946077</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Bleiler</surname><given-names>TW</given-names></name><article-title>2013 Alzheimer&#x02019;s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>208</fpage><lpage>245</lpage><comment>[<ext-link ext-link-type="uri" xlink:href="http://www.alz.org/downloads/facts_figures_2013.pdf">http://www.alz.org/downloads/facts_figures_2013.pdf</ext-link>]</comment><pub-id pub-id-type="pmid">23507120</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Alzheimer&#x02019;s disease results from the cerebral accumulation and cytotoxicity
of amyloid &#x003b2;-protein</article-title><source>J Alzheimers Dis</source><year>2001</year><volume>3</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12214075</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>A&#x003b2; oligomers - a decade of discovery</article-title><source>J Neurochem</source><year>2007</year><volume>101</volume><fpage>1172</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04426.x</pub-id><pub-id pub-id-type="pmid">17286590</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Roychaudhuri</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Hoshi</surname><given-names>MM</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Amyloid &#x003b2;-protein assembly and Alzheimer disease</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>4749</fpage><lpage>4753</lpage><pub-id pub-id-type="doi">10.1074/jbc.R800036200</pub-id><pub-id pub-id-type="pmid">18845536</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Ondrejcak</surname><given-names>T</given-names></name><name><surname>Klyubin</surname><given-names>I</given-names></name><name><surname>Hu</surname><given-names>N-W</given-names></name><name><surname>Barry</surname><given-names>AE</given-names></name><name><surname>Cullen</surname><given-names>WK</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><article-title>Alzheimer&#x02019;s disease amyloid &#x003b2;-protein and synaptic function</article-title><source>Neuromol Med</source><year>2010</year><volume>12</volume><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s12017-009-8091-0</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Sakono</surname><given-names>M</given-names></name><name><surname>Zako</surname><given-names>T</given-names></name><article-title>Amyloid oligomers: formation and toxicity of A&#x003b2; oligomers</article-title><source>FEBS J</source><year>2010</year><volume>277</volume><fpage>1348</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07568.x</pub-id><pub-id pub-id-type="pmid">20148964</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Ferreira</surname><given-names>ST</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>The A&#x003b2; oligomer hypothesis for synapse failure and memory loss in
Alzheimer&#x02019;s disease</article-title><source>Neurobiol Learn Mem</source><year>2011</year><volume>96</volume><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2011.08.003</pub-id><pub-id pub-id-type="pmid">21914486</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Benilova</surname><given-names>I</given-names></name><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><article-title>The toxic A&#x003b2; oligomer and Alzheimer&#x02019;s disease: an emperor in need of
clothes</article-title><source>Nat Neurosci</source><year>2012</year><volume>15</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nn.3028</pub-id><pub-id pub-id-type="pmid">22286176</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Hayden</surname><given-names>EY</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Amyloid &#x003b2;-protein oligomers and Alzheimer&#x02019;s disease</article-title><source>Alzheimers Res Ther</source><year>2013</year><volume>5</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/alzrt226</pub-id><pub-id pub-id-type="pmid">24289820</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>CW</given-names></name><name><surname>Quaranta</surname><given-names>V</given-names></name><name><surname>Glenner</surname><given-names>GG</given-names></name><article-title>Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are
antigenically related</article-title><source>Proc Natl Acad Sci USA</source><year>1985</year><volume>82</volume><fpage>8729</fpage><lpage>8732</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.24.8729</pub-id><pub-id pub-id-type="pmid">2934737</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Higgins</surname><given-names>GA</given-names></name><article-title>Alzheimer&#x02019;s disease: the amyloid cascade hypothesis</article-title><source>Science</source><year>1992</year><volume>256</volume><fpage>184</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1126/science.1566067</pub-id><pub-id pub-id-type="pmid">1566067</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><article-title>Targeting small A&#x003b2; oligomers: the solution to an Alzheimer&#x02019;s disease
conundrum?</article-title><source>Trends Neurosci</source><year>2001</year><volume>24</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(00)01749-5</pub-id><pub-id pub-id-type="pmid">11250006</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>De Felice</surname><given-names>FG</given-names></name><name><surname>Ferreira</surname><given-names>ST</given-names></name><article-title>&#x003b2;-Amyloid production, aggregation, and clearance as targets for therapy in
Alzheimer&#x02019;s disease</article-title><source>Cell Mol Neurobiol</source><year>2002</year><volume>22</volume><fpage>545</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1023/A:1021832302524</pub-id><pub-id pub-id-type="pmid">12585679</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Citron</surname><given-names>M</given-names></name><article-title>Strategies for disease modification in Alzheimer&#x02019;s disease</article-title><source>Nat Rev Neurosci</source><year>2004</year><volume>5</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/nrn1495</pub-id><pub-id pub-id-type="pmid">15322526</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Haas</surname><given-names>C</given-names></name><article-title>Initiation and propagation of neurodegeneration</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><fpage>1201</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1038/nm.2223</pub-id><pub-id pub-id-type="pmid">21052073</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Broersen</surname><given-names>K</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Schymkowitz</surname><given-names>J</given-names></name><article-title>The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer&#x02019;s
disease: oligomer size or conformation</article-title><source>Alzheimers Res Ther</source><year>2010</year><volume>2</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/alzrt36</pub-id><pub-id pub-id-type="pmid">20642866</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Wilcox</surname><given-names>KC</given-names></name><name><surname>Lacor</surname><given-names>RN</given-names></name><name><surname>Pitt</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>A&#x003b2; oligomer-induced synapse degeneration in Alzheimer&#x02019;s disease</article-title><source>Cell Mol Neurobiol</source><year>2011</year><volume>31</volume><fpage>939</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1007/s10571-011-9691-4</pub-id><pub-id pub-id-type="pmid">21538118</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Moreth</surname><given-names>J</given-names></name><name><surname>Kroker</surname><given-names>KS</given-names></name><name><surname>Schwanzar</surname><given-names>D</given-names></name><name><surname>Schnack</surname><given-names>C</given-names></name><name><surname>von Arnim</surname><given-names>CAF</given-names></name><name><surname>Hengerer</surname><given-names>B</given-names></name><name><surname>Rosenbrock</surname><given-names>H</given-names></name><name><surname>Kussmaul</surname><given-names>L</given-names></name><article-title>Globular and protofibrillar A&#x003b2; aggregates impair neurotransmission by
different mechanism</article-title><source>Biochem</source><year>2013</year><volume>52</volume><fpage>1466</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1021/bi3016444</pub-id><pub-id pub-id-type="pmid">23374097</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Lamakin</surname><given-names>A</given-names></name><name><surname>Benedek</surname><given-names>GB</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Amyloid &#x003b2;-protein fibrillogenesis: detection of a protofibrillar
intermediated</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>22364</fpage><lpage>22372</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.35.22364</pub-id><pub-id pub-id-type="pmid">9268388</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Fezoui</surname><given-names>Y</given-names></name><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Harper</surname><given-names>JD</given-names></name><name><surname>Khurana</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names></name><name><surname>Finnk</surname><given-names>AL</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>An improved method of preparing the amyloid &#x003b2;-protein for fibrillogenesis and
neurotoxicity experiments</article-title><source>Amyloid</source><year>2000</year><volume>7</volume><fpage>166</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3109/13506120009146831</pub-id><pub-id pub-id-type="pmid">11019857</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Fernandez</surname><given-names>EJ</given-names></name><name><surname>Good</surname><given-names>TA</given-names></name><article-title>Role of aggregation conditions in structure, stability, and toxicity of
intermediates in the A&#x003b2; fibril formation pathway</article-title><source>Protein Sci</source><year>2007</year><volume>16</volume><fpage>723</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1110/ps.062514807</pub-id><pub-id pub-id-type="pmid">17327396</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Paravastu</surname><given-names>AK</given-names></name><name><surname>Qahwash</surname><given-names>I</given-names></name><name><surname>Leapman</surname><given-names>RD</given-names></name><name><surname>Meredith</surname><given-names>SC</given-names></name><name><surname>Tycko</surname><given-names>R</given-names></name><article-title>Seeded growth of &#x003b2;-amyloid fibrils from Alzheimer&#x02019;s brain-derived
fibrils produces a distinct fibril structure</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>7443</fpage><lpage>7448</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812033106</pub-id><pub-id pub-id-type="pmid">19376973</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Norlin</surname><given-names>N</given-names></name><name><surname>Hellberg</surname><given-names>M</given-names></name><name><surname>Filippov</surname><given-names>A</given-names></name><name><surname>Sousa</surname><given-names>AA</given-names></name><name><surname>Gr&#x000f6;bner</surname><given-names>G</given-names></name><name><surname>Leapman</surname><given-names>RD</given-names></name><name><surname>Almqvist</surname><given-names>N</given-names></name><name><surname>Antzutkin</surname><given-names>ON</given-names></name><article-title>Aggregation and fibril morphology of the Arctic mutation of Alzheimer&#x02019;s
A&#x003b2; peptide by CD, TEM, STEM and <italic>in situ</italic> AFM</article-title><source>J Struct Biol</source><year>2012</year><volume>180</volume><fpage>174</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2012.06.010</pub-id><pub-id pub-id-type="pmid">22750418</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Morgado</surname><given-names>I</given-names></name><name><surname>F&#x000e4;ndrich</surname><given-names>M</given-names></name><article-title>Assembly of Alzheimer&#x02019;s A&#x003b2; peptide into nanostructured amyloid
fibrils</article-title><source>Curr Opin Colloid Interface Sci</source><year>2011</year><volume>16</volume><fpage>508</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.cocis.2011.06.016</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Tekirian</surname><given-names>TL</given-names></name><name><surname>Yang</surname><given-names>AY</given-names></name><name><surname>Glabe</surname><given-names>C</given-names></name><name><surname>Geddes</surname><given-names>JW</given-names></name><article-title>Toxicity of pyroglutaminated amyloid &#x003b2;-peptides 3(pE)-40 and -42 is similar
to that of A&#x003b2;1-40 and -42</article-title><source>J Neurochem</source><year>1999</year><volume>73</volume><fpage>1584</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">10501204</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Roher</surname><given-names>AE</given-names></name><name><surname>Lowenson</surname><given-names>JD</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>AS</given-names></name><name><surname>Cotter</surname><given-names>RJ</given-names></name><name><surname>Gowing</surname><given-names>E</given-names></name><name><surname>Ball</surname><given-names>ML</given-names></name><article-title>&#x003b2;-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits:
implications for the pathology of Alzheimer disease</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>10836</fpage><lpage>10840</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.22.10836</pub-id><pub-id pub-id-type="pmid">8248178</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Capetillo-Zarate</surname><given-names>E</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><article-title>The development of amyloid beta protein deposits in the aged brain</article-title><source>Sci Aging Knowledge Environ</source><year>2006</year><volume>2006</volume><fpage>re1</fpage><pub-id pub-id-type="pmid">16525193</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Podlisny</surname><given-names>MB</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Squazzo</surname><given-names>SL</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Rydell</surname><given-names>RE</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Aggregation of secreted amyloid &#x003b2;-protein into sodium dodecyl sulfate-stable
oligomers in cell culture</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>9564</fpage><lpage>9570</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.16.9564</pub-id><pub-id pub-id-type="pmid">7721886</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Klyubin</surname><given-names>I</given-names></name><name><surname>Fadeeva</surname><given-names>JV</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Amyloid-&#x003b2; oligomers: their production, toxicity and therapeutic
inhibition</article-title><source>Biochem Soc Trans</source><year>2002</year><volume>30</volume><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">12196135</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Cleary</surname><given-names>JP</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Hofmeister</surname><given-names>JJ</given-names></name><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Kushowski</surname><given-names>MA</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><article-title>Natural oligomers of the amyloid-&#x003b2; protein specifically disrupt cognitive
function</article-title><source>Nat Neurosci</source><year>2005</year><volume>8</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/nn1372</pub-id><pub-id pub-id-type="pmid">15608634</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Cleary</surname><given-names>JP</given-names></name><name><surname>Mehta</surname><given-names>T</given-names></name><name><surname>Hofmeister</surname><given-names>J</given-names></name><name><surname>Lesne</surname><given-names>S</given-names></name><name><surname>O&#x02019;Hare</surname><given-names>E</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Orally available compound prevents deficits in memory caused by the Alzheimer
amyloid-&#x003b2; oligomers</article-title><source>Ann Neurol</source><year>2006</year><volume>60</volume><fpage>668</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1002/ana.21051</pub-id><pub-id pub-id-type="pmid">17192927</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>MN</given-names></name><name><surname>Hofmeister</surname><given-names>JJ</given-names></name><name><surname>Jungbauer</surname><given-names>L</given-names></name><name><surname>Welzel</surname><given-names>AT</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Sherman</surname><given-names>MA</given-names></name><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>LaDu</surname><given-names>MJ</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><name><surname>Cleary</surname><given-names>JP</given-names></name><article-title>Cognitive effects of cell-derived and synthetically derived A&#x003b2; oligomers</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><fpage>1784</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.11.007</pub-id><pub-id pub-id-type="pmid">20031278</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Freir</surname><given-names>DB</given-names></name><name><surname>Fedriani</surname><given-names>R</given-names></name><name><surname>Scully</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>IM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Regan</surname><given-names>CM</given-names></name><article-title>A&#x003b2; oligomers inhibit synapse remodeling necessary for memory
consolidation</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><fpage>2211</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.01.001</pub-id><pub-id pub-id-type="pmid">20097446</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>TH</given-names></name><name><surname>Garcia-Munoz</surname><given-names>A</given-names></name><name><surname>Shepardson</surname><given-names>NE</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Brett</surname><given-names>FM</given-names></name><name><surname>Farrell</surname><given-names>MA</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Regan</surname><given-names>CM</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Amyloid-&#x003b2; protein dimers isolated directly from Alzheimer&#x02019;s brains
impair synaptic plasticity and memory</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>837</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1038/nm1782</pub-id><pub-id pub-id-type="pmid">18568035</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Mehta</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Effects of secreted oligomers of amyloid &#x003b2;-protein on hippocampal synaptic
plasticity: a potent role for trimers</article-title><source>J Physiol</source><year>2006</year><volume>572</volume><fpage>477</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2005.103754</pub-id><pub-id pub-id-type="pmid">16469784</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>MT</given-names></name><name><surname>Kotilinek</surname><given-names>L</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Gallagher</surname><given-names>M</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><article-title>A specific amyloid-&#x003b2; protein assembly in the brain impairs memory</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>352</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature04533</pub-id><pub-id pub-id-type="pmid">16541076</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y-R</given-names></name><name><surname>Clabe</surname><given-names>CG</given-names></name><article-title>Distinct early folding and aggregation properties of Alzheimer amyloid-&#x003b2;
peptides A&#x003b2;40 and A&#x003b2;42</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>24414</fpage><lpage>24422</lpage><pub-id pub-id-type="doi">10.1074/jbc.M602363200</pub-id><pub-id pub-id-type="pmid">16809342</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Bitan</surname><given-names>G</given-names></name><name><surname>Vollers</surname><given-names>SS</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Elucidation of primary structure elements controlling early amyloid &#x003b2;-protein
oligomerization</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>34882</fpage><lpage>34889</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300825200</pub-id><pub-id pub-id-type="pmid">12840029</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Barghorn</surname><given-names>S</given-names></name><name><surname>Nimmrich</surname><given-names>V</given-names></name><name><surname>Striebinger</surname><given-names>A</given-names></name><name><surname>Krantz</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>P</given-names></name><name><surname>Janson</surname><given-names>B</given-names></name><name><surname>Bahr</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Bitner</surname><given-names>RS</given-names></name><name><surname>Harlan</surname><given-names>J</given-names></name><name><surname>Barlow</surname><given-names>E</given-names></name><name><surname>Ebert</surname><given-names>U</given-names></name><name><surname>Hillen</surname><given-names>H</given-names></name><article-title>Globular amyloid &#x003b2;-peptide<sub>1-42</sub> oligomer - a homogenous and stable
neuropathological protein in Alzheimer&#x02019;s disease</article-title><source>J Neurochem</source><year>2005</year><volume>95</volume><fpage>834</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03407.x</pub-id><pub-id pub-id-type="pmid">16135089</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Larson</surname><given-names>ME</given-names></name><name><surname>Lesn&#x000e9;</surname><given-names>SE</given-names></name><article-title>Soluble A&#x003b2; oligomer production and toxicity</article-title><source>J Neurochem</source><year>2012</year><volume>120</volume><issue>Suppl 1</issue><fpage>125</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">22121920</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Barlow</surname><given-names>AK</given-names></name><name><surname>Chromy</surname><given-names>BA</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><name><surname>Freed</surname><given-names>R</given-names></name><name><surname>Liosatos</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Rozovsky</surname><given-names>I</given-names></name><name><surname>Trommer</surname><given-names>B</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Wals</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>Diffusible, non-fibrillar ligands derived from A&#x003b2;1-42 are potent central
nervous system neurotoxins</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>6448</fpage><lpage>6453</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.11.6448</pub-id><pub-id pub-id-type="pmid">9600986</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Stine</surname><given-names>WB</given-names></name><name><surname>Dahlgren</surname><given-names>KN</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>LaDu</surname><given-names>MJ</given-names></name><article-title><italic>In vitro</italic> characterization of conditions for amyloid-&#x003b2; peptide
oligomerization and fibrillogenesis</article-title><source>J Mol Biol</source><year>2003</year><volume>278</volume><fpage>11612</fpage><lpage>11622</lpage></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Hepler</surname><given-names>RW</given-names></name><name><surname>Grimm</surname><given-names>KM</given-names></name><name><surname>Nahas</surname><given-names>DD</given-names></name><name><surname>Breese</surname><given-names>R</given-names></name><name><surname>Dodson</surname><given-names>EC</given-names></name><name><surname>Acton</surname><given-names>P</given-names></name><name><surname>Keller</surname><given-names>PM</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shughrue</surname><given-names>P</given-names></name><name><surname>Kinney</surname><given-names>G</given-names></name><name><surname>Joyce</surname><given-names>JG</given-names></name><article-title>Solution state characterization of amyloid &#x003b2;-derived diffusible ligands</article-title><source>Biochem</source><year>2006</year><volume>45</volume><fpage>15157</fpage><lpage>15167</lpage><pub-id pub-id-type="doi">10.1021/bi061850f</pub-id><pub-id pub-id-type="pmid">17176037</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Deshpande</surname><given-names>A</given-names></name><name><surname>Mina</surname><given-names>E</given-names></name><name><surname>Glabe</surname><given-names>C</given-names></name><name><surname>Busciglio</surname><given-names>J</given-names></name><article-title>Different conformations of amyloid &#x003b2; induce neurotoxicity by distinct
mechanisms in human cortical neurons</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>6011</fpage><lpage>6018</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1189-06.2006</pub-id><pub-id pub-id-type="pmid">16738244</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Head</surname><given-names>E</given-names></name><name><surname>Sarsoza</surname><given-names>F</given-names></name><name><surname>Saing</surname><given-names>T</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Necula</surname><given-names>M</given-names></name><name><surname>Margol</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Breydo</surname><given-names>L</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>Rasool</surname><given-names>S</given-names></name><name><surname>Gurlo</surname><given-names>T</given-names></name><name><surname>Butler</surname><given-names>P</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><article-title>Fibril specific, conformation depended antibodies recognize a generic epitope
common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar
oligomers</article-title><source>Mol Neurodegen</source><year>2007</year><volume>2</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-2-18</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Rangachari</surname><given-names>V</given-names></name><name><surname>Moore</surname><given-names>BD</given-names></name><name><surname>Reed</surname><given-names>DK</given-names></name><name><surname>Sonoda</surname><given-names>LK</given-names></name><name><surname>Bridges</surname><given-names>AW</given-names></name><name><surname>Conboy</surname><given-names>E</given-names></name><name><surname>Hartigan</surname><given-names>D</given-names></name><name><surname>Rosenberry</surname><given-names>TL</given-names></name><article-title>Amyloid-&#x003b2;(1-42) rapidly forms protofibrils and oligomers by distinct pathways
in low concentrations of sodium dodecylsulfate</article-title><source>Biochem</source><year>2007</year><volume>46</volume><fpage>12451</fpage><lpage>12462</lpage><pub-id pub-id-type="doi">10.1021/bi701213s</pub-id><pub-id pub-id-type="pmid">17910477</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Gellermann</surname><given-names>GP</given-names></name><name><surname>Byrnes</surname><given-names>H</given-names></name><name><surname>Striebinger</surname><given-names>A</given-names></name><name><surname>Ullrich</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>R</given-names></name><name><surname>Hillen</surname><given-names>H</given-names></name><name><surname>Barghorn</surname><given-names>S</given-names></name><article-title>A&#x003b2;-globulomers are formed independently of the fibril pathway</article-title><source>Neurobiol Dis</source><year>2008</year><volume>30</volume><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2008.01.010</pub-id><pub-id pub-id-type="pmid">18353662</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Nimmrich</surname><given-names>V</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Draguhn</surname><given-names>A</given-names></name><name><surname>Barghorn</surname><given-names>S</given-names></name><name><surname>Lehmann</surname><given-names>A</given-names></name><name><surname>Schoemaker</surname><given-names>H</given-names></name><name><surname>Hillen</surname><given-names>H</given-names></name><name><surname>Gross</surname><given-names>G</given-names></name><name><surname>Ebert</surname><given-names>U</given-names></name><name><surname>Bruehl</surname><given-names>C</given-names></name><article-title>Amyloid &#x003b2; oligomers (A&#x003b2;1-42 globulomer) suppress spontaneous synaptic
activity by inhibition of P/Q-type calcium currents</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>788</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4771-07.2008</pub-id><pub-id pub-id-type="pmid">18216187</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Demuro</surname><given-names>A</given-names></name><name><surname>Mina</surname><given-names>E</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Milton</surname><given-names>SC</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><article-title>Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism
of soluble amyloid oligomers</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>17294</fpage><lpage>17300</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500997200</pub-id><pub-id pub-id-type="pmid">15722360</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Hoshi</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Noguchi</surname><given-names>A</given-names></name><name><surname>Yasutake</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><article-title>Spherical aggregates of &#x003b2;-amyloid (amylospheroid) show high neurotoxicity and
activate tau protein kinase I/glycogen synthase kinase-3&#x003b2;</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>6370</fpage><lpage>6575</lpage><pub-id pub-id-type="doi">10.1073/pnas.1237107100</pub-id><pub-id pub-id-type="pmid">12750461</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Noguchi</surname><given-names>A</given-names></name><name><surname>Matsumura</surname><given-names>S</given-names></name><name><surname>Dezawa</surname><given-names>M</given-names></name><name><surname>Tada</surname><given-names>M</given-names></name><name><surname>Yanazawa</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Akioka</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Ideno</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Fukunari</surname><given-names>A</given-names></name><name><surname>Muramatsu</surname><given-names>S-i</given-names></name><name><surname>Itokazu</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Nabeshima</surname><given-names>Y-i</given-names></name><name><surname>Kakita</surname><given-names>A</given-names></name><name><surname>Imahori</surname><given-names>K</given-names></name><name><surname>Hoshi</surname><given-names>M</given-names></name><article-title>Isolation and characterization of patient-derived, toxic, high mass amyloid
&#x003b2;-protein (A&#x003b2;) assembly from Alzheimer disease brains</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>32895</fpage><lpage>32905</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.000208</pub-id><pub-id pub-id-type="pmid">19759000</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Kusumoto</surname><given-names>Y</given-names></name><name><surname>Fezoui</surname><given-names>Y</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Lomakin</surname><given-names>AL</given-names></name><name><surname>Benedek</surname><given-names>GB</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Amyloid &#x003b2;-protein fibrillogenesis: structure and biological activity of
protofibrillar intermediates</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>25945</fpage><lpage>25952</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.36.25945</pub-id><pub-id pub-id-type="pmid">10464339</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Harper</surname><given-names>JD</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Lieber</surname><given-names>CM</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names><suffix>Jr</suffix></name><article-title>Assembly of A&#x003b2; amyloid protofibrils: an in vitro model for a possible early
event in Alzheimer&#x02019;s disease</article-title><source>Biochem</source><year>1999</year><volume>38</volume><fpage>8972</fpage><lpage>8980</lpage><pub-id pub-id-type="doi">10.1021/bi9904149</pub-id><pub-id pub-id-type="pmid">10413470</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Petre</surname><given-names>BM</given-names></name><name><surname>Wall</surname><given-names>JS</given-names></name><name><surname>Simon</surname><given-names>MN</given-names></name><name><surname>Walz</surname><given-names>T</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names></name><article-title>Mixtures of wild-type and a pathogenic (E22G) form of A&#x003b2;40 <italic>in vitro</italic>
accumulate protofibrils, including amyloid pores</article-title><source>J Mol Biol</source><year>2003</year><volume>332</volume><fpage>795</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(03)00927-6</pub-id><pub-id pub-id-type="pmid">12972252</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><article-title>Amyloid-&#x003b2; annular protofibrils evade fibrillar fate in Alzheimer disease
brain</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>22122</fpage><lpage>22130</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.236257</pub-id><pub-id pub-id-type="pmid">21507938</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Mehta</surname><given-names>PD</given-names></name><name><surname>Pirttil&#x000e4;</surname><given-names>T</given-names></name><name><surname>Mehta</surname><given-names>SP</given-names></name><name><surname>Sersen</surname><given-names>EA</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Wisniewski</surname><given-names>HM</given-names></name><article-title>Plasma and cerebrospinal fluid levels of amyloid &#x003b2; proteins 1-40 and 1-42 in
Alzheimer disease</article-title><source>Arch Neurol</source><year>2000</year><volume>57</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1001/archneur.57.1.100</pub-id><pub-id pub-id-type="pmid">10634455</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Delacourte</surname><given-names>A</given-names></name><name><surname>Sergeant</surname><given-names>N</given-names></name><name><surname>Champain</surname><given-names>D</given-names></name><name><surname>Wattez</surname><given-names>A</given-names></name><name><surname>Maurage</surname><given-names>C-A</given-names></name><name><surname>Lebert</surname><given-names>F</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>David</surname><given-names>J-P</given-names></name><article-title>Nonoverlapping but synergetic tau and APP pathologies in sporadic
Alzheimer&#x02019;s disease</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>398</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1212/WNL.59.3.398</pub-id><pub-id pub-id-type="pmid">12177374</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Fukumoto</surname><given-names>H</given-names></name><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Kasai</surname><given-names>T</given-names></name><name><surname>Ishigami</surname><given-names>N</given-names></name><name><surname>Hidaka</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><article-title>High-molecular-weight &#x003b2;-amyloid oligomers are elevated in cerebrospinal fluid
of Alzheimer patients</article-title><source>FASEB J</source><year>2010</year><volume>24</volume><fpage>2716</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1096/fj.09-150359</pub-id><pub-id pub-id-type="pmid">20339023</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><name><surname>De Stropper</surname><given-names>B</given-names></name><article-title>The amyloid cascade hypothesis for Alzheimer&#x02019;s disease: an appraisal for the
development of therapeutics</article-title><source>Nat Rev Drug Disc</source><year>2011</year><volume>10</volume><fpage>698</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/nrd3505</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>A</given-names></name><name><surname>McCampbell</surname><given-names>A</given-names></name><name><surname>Hatcher</surname><given-names>N</given-names></name><name><surname>Tugusheva</surname><given-names>K</given-names></name><name><surname>Haugabook</surname><given-names>S</given-names></name><name><surname>Maxwell</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Howell</surname><given-names>B</given-names></name><name><surname>Renger</surname><given-names>J</given-names></name><name><surname>Shughrue</surname><given-names>P</given-names></name><name><surname>Savage</surname><given-names>M</given-names></name><article-title>A quantitative assay selective for amyloid oligomer species differentiates
cerebrospinal fluid from Alzheimer&#x02019;s disease and age-matched normal</article-title><source>Alzheimers Dementia</source><year>2012</year><volume>8</volume><issue>Supplement</issue><fpage>P278</fpage></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>H&#x000f6;ltt&#x000e4;</surname><given-names>M</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Hertze</surname><given-names>J</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>N&#x000e4;gga</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Evaluating amyloid-&#x003b2; oligomers in cerebrospinal fluid as a biomarker for
Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e66381</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0066381</pub-id><pub-id pub-id-type="pmid">23799095</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Lue</surname><given-names>L-F</given-names></name><name><surname>Kuo</surname><given-names>Y-M</given-names></name><name><surname>Roher</surname><given-names>AE</given-names></name><name><surname>Brachova</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Sue</surname><given-names>L</given-names></name><name><surname>Beach</surname><given-names>T</given-names></name><name><surname>Kurth</surname><given-names>JH</given-names></name><name><surname>Rydel</surname><given-names>RE</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><article-title>Soluble amyloid &#x003b2; peptide concentration as a predictor of synaptic change in
Alzheimer&#x02019;s disease</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65184-X</pub-id><pub-id pub-id-type="pmid">10487842</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>McDonald</surname><given-names>JM</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Taylor-Reinwald</surname><given-names>L</given-names></name><name><surname>Holtzman</surname><given-names>D</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><article-title>The levels of water-soluble and triton-soluble A&#x003b2; are increased in
Alzheimer&#x02019;s disease brain</article-title><source>Brain Res</source><year>2012</year><volume>1450</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">22440675</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Savage</surname><given-names>MJ</given-names></name><name><surname>Kalinina</surname><given-names>J</given-names></name><name><surname>Wolfe</surname><given-names>A</given-names></name><name><surname>Tugusheva</surname><given-names>K</given-names></name><name><surname>Korn</surname><given-names>R</given-names></name><name><surname>Cash-Mason</surname><given-names>T</given-names></name><name><surname>Maxwell</surname><given-names>JW</given-names></name><name><surname>Hatcher</surname><given-names>NG</given-names></name><name><surname>Haugabook</surname><given-names>SJ</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Howell</surname><given-names>BJ</given-names></name><name><surname>Renger</surname><given-names>JJ</given-names></name><name><surname>Shughrue</surname><given-names>PJ</given-names></name><name><surname>McCampbell</surname><given-names>A</given-names></name><article-title>A sensitive A&#x003b2; oligomer assay discriminates Alzheimer&#x02019;s and aged
control cerebrospinal fluid</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>2884</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1675-13.2014</pub-id><pub-id pub-id-type="pmid">24553930</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>RD</given-names></name><name><surname>Schauerte</surname><given-names>JA</given-names></name><name><surname>Wisser</surname><given-names>KC</given-names></name><name><surname>Gafni</surname><given-names>A</given-names></name><name><surname>Steel</surname><given-names>DG</given-names></name><article-title>Direct observation of single amyloid-&#x003b2;(1-40) oligomers on live cells: binding
and growth at physiological concentrations</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e23970</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0023970</pub-id><pub-id pub-id-type="pmid">21901146</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>RD</given-names></name><name><surname>Schauerte</surname><given-names>JA</given-names></name><name><surname>Chang</surname><given-names>C-C</given-names></name><name><surname>Wisser</surname><given-names>KC</given-names></name><name><surname>Althaus</surname><given-names>JC</given-names></name><name><surname>Carruthers</surname><given-names>CJL</given-names></name><name><surname>Sutton</surname><given-names>MA</given-names></name><name><surname>Steel</surname><given-names>DG</given-names></name><name><surname>Gafni</surname><given-names>A</given-names></name><article-title>Single-molecule imaging reveals A&#x003b2;42:A&#x003b2;40 ratio-dependent oligomer
growth on neuronal processes</article-title><source>Biophys J</source><year>2013</year><volume>104</volume><fpage>894</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2012.12.051</pub-id><pub-id pub-id-type="pmid">23442968</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Lansbury</surname><given-names>PT</given-names></name><article-title>Evolution of amyloid: what normal protein folding may tell us about
fibrillogenesis and disease</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>3342</fpage><lpage>3344</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.7.3342</pub-id><pub-id pub-id-type="pmid">10097040</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Serpell</surname><given-names>LC</given-names></name><article-title>Alzheimer&#x02019;s amyloid fibrils: structure and assembly</article-title><source>Biochim Biophys Acta</source><year>2000</year><volume>1502</volume><fpage>16</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0925-4439(00)00029-6</pub-id><pub-id pub-id-type="pmid">10899428</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Blackley</surname><given-names>HK</given-names></name><name><surname>Sanders</surname><given-names>GH</given-names></name><name><surname>Davies</surname><given-names>MC</given-names></name><name><surname>Roberts</surname><given-names>CJ</given-names></name><name><surname>Tendler</surname><given-names>SJ</given-names></name><name><surname>Wilkinson</surname><given-names>MJ</given-names></name><article-title>In-situ atomic force microscopy study of &#x003b2;-amyloid fibrillization</article-title><source>J Mol Biol</source><year>2000</year><volume>298</volume><fpage>833</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2000.3711</pub-id><pub-id pub-id-type="pmid">10801352</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Kirkitadze</surname><given-names>MD</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Identification and characterization of key kinetic intermediates in amyloid
&#x003b2;-protein fibrillogenesis</article-title><source>J Mol Biol</source><year>2001</year><volume>312</volume><fpage>1103</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2001.4970</pub-id><pub-id pub-id-type="pmid">11580253</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name><surname>Caughey</surname><given-names>B</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names></name><article-title>Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible
protein aggregates from the innocent bystanders</article-title><source>Annu Rev Neurosci</source><year>2003</year><volume>26</volume><fpage>267</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.26.010302.081142</pub-id><pub-id pub-id-type="pmid">12704221</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>SI</given-names></name><name><surname>Linse</surname><given-names>S</given-names></name><name><surname>Luheshi</surname><given-names>LM</given-names></name><name><surname>Hellstrand</surname><given-names>E</given-names></name><name><surname>White</surname><given-names>DA</given-names></name><name><surname>Rajah</surname><given-names>L</given-names></name><name><surname>Otzen</surname><given-names>DE</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Knowles</surname><given-names>TP</given-names></name><article-title>Proliferation of amyloid-&#x003b2;42 aggregates occurs through a secondary nucleation
mechanism</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>9758</fpage><lpage>9763</lpage><pub-id pub-id-type="doi">10.1073/pnas.1218402110</pub-id><pub-id pub-id-type="pmid">23703910</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name><surname>Jeong</surname><given-names>JS</given-names></name><name><surname>Ansaloni</surname><given-names>A</given-names></name><name><surname>Mezzenga</surname><given-names>R</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Dietler</surname><given-names>G</given-names></name><article-title>Novel mechanistic insight into the molecular basis of amyloid polymorphism and
secondary nucleation during amyloid formation</article-title><source>J Mol Biol</source><year>2013</year><volume>425</volume><fpage>1765</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2013.02.005</pub-id><pub-id pub-id-type="pmid">23415897</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name><surname>Stefani</surname><given-names>M</given-names></name><article-title>Biochemical and biophysical features of both oligomer/fibril and cell membrane in
amyloid cytotoxicity</article-title><source>FEBS J</source><year>2010</year><volume>277</volume><fpage>4602</fpage><lpage>4613</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07889.x</pub-id><pub-id pub-id-type="pmid">20977664</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><name><surname>Lanz</surname><given-names>TA</given-names></name><name><surname>Himes</surname><given-names>CS</given-names></name><name><surname>Pallante</surname><given-names>G</given-names></name><name><surname>Adams</surname><given-names>L</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Amore</surname><given-names>B</given-names></name><name><surname>Merchant</surname><given-names>KM</given-names></name><article-title><bold>The</bold> &#x003b3;<bold>-secretase inhibitor
N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces
A&#x003b2; levels in vivo in plasma and cerebrospinal fluid in young (plaque-free)
and aged (plaque-bearing) Tg2576 mice</bold></article-title><source>J Pharmacol Exp Ther</source><year>2003</year><volume>305</volume><fpage>864</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1124/jpet.102.048280</pub-id><pub-id pub-id-type="pmid">12626636</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name><surname>Barten</surname><given-names>DM</given-names></name><name><surname>Guss</surname><given-names>VL</given-names></name><name><surname>Corsa</surname><given-names>JA</given-names></name><name><surname>Loo</surname><given-names>A</given-names></name><name><surname>Hansel</surname><given-names>SB</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>B</given-names></name><name><surname>Srinivasan</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Robertson</surname><given-names>BJ</given-names></name><name><surname>Polson</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>SB</given-names></name><name><surname>Hendrick</surname><given-names>JP</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>Loy</surname><given-names>JK</given-names></name><name><surname>Denton</surname><given-names>R</given-names></name><name><surname>Verdoorn</surname><given-names>TA</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Felsenstein</surname><given-names>KM</given-names></name><article-title>Dynamics of &#x003b2;-amyloid reductions in brain, cerebrospinal fluid, and plasma of
&#x003b2;-amyloid precursor protein transgenic mice treated with a &#x003b3;-secretase
inhibitor</article-title><source>J Pharmacol Exp Ther</source><year>2005</year><volume>312</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">15452193</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Wiederhold</surname><given-names>K-H</given-names></name><name><surname>Furrer</surname><given-names>U</given-names></name><name><surname>Jaton</surname><given-names>A-L</given-names></name><name><surname>Neuenschwander</surname><given-names>A</given-names></name><name><surname>Runser</surname><given-names>M-J</given-names></name><name><surname>Danner</surname><given-names>S</given-names></name><name><surname>Reichwald</surname><given-names>J</given-names></name><name><surname>Ammaturo</surname><given-names>D</given-names></name><name><surname>Staab</surname><given-names>D</given-names></name><name><surname>Stoeckli</surname><given-names>M</given-names></name><name><surname>Rueeger</surname><given-names>H</given-names></name><name><surname>Neumann</surname><given-names>U</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><article-title>Dynamics of A&#x003b2; turnover and deposition in different &#x003b2;-amyloid precursor
protein transgenic mouse models following &#x003b3;-secretase inhibition</article-title><source>J Pharmacol Exp Ther</source><year>2008</year><volume>327</volume><fpage>411</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1124/jpet.108.140327</pub-id><pub-id pub-id-type="pmid">18687920</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>Subramanian</surname><given-names>M</given-names></name><name><surname>Thyssen</surname><given-names>D</given-names></name><name><surname>Borrelli</surname><given-names>LA</given-names></name><name><surname>Fauq</surname><given-names>A</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Bacskai</surname><given-names>BJ</given-names></name><article-title>Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by
administration of the gamma-secretase inhibitor LY-411575</article-title><source>Mol Neurodegen</source><year>2009</year><volume>4</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-4-19</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name><surname>Jankowsky</surname><given-names>JL</given-names></name><name><surname>Slunt</surname><given-names>HH</given-names></name><name><surname>Gonzales</surname><given-names>V</given-names></name><name><surname>Savonenko</surname><given-names>AV</given-names></name><name><surname>Wen</surname><given-names>JC</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Younkin</surname><given-names>LH</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Borchelt</surname><given-names>DR</given-names></name><article-title>Persistent amyloidosis following suppression of A&#x003b2; production in a transgenic
model of Alzheimer disease</article-title><source>PLoS Med</source><year>2005</year><volume>2</volume><fpage>e355</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0020355</pub-id><pub-id pub-id-type="pmid">16279840</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name><surname>Melnikova</surname><given-names>T</given-names></name><name><surname>Fromholt</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Price</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>BD</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Felsenstein</surname><given-names>KM</given-names></name><name><surname>Savonenko</surname><given-names>A</given-names></name><name><surname>Borchelt</surname><given-names>DR</given-names></name><article-title>Reversible pathologic and cognitive phenotypes in an inducible model of
Alzheimer-amyloidosis</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>3765</fpage><lpage>3779</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4251-12.2013</pub-id><pub-id pub-id-type="pmid">23447589</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Younkin</surname><given-names>LA</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><article-title>Reduced effectiveness of A&#x003b2;1-42 immunization in APP transgenic mice with
significant amyloid deposition</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><fpage>721</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(01)00245-7</pub-id><pub-id pub-id-type="pmid">11705631</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>IH</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Legleiter</surname><given-names>J</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Gerstein</surname><given-names>H</given-names></name><name><surname>Bien-Ly</surname><given-names>N</given-names></name><name><surname>Puoliv&#x000e4;li</surname><given-names>J</given-names></name><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><name><surname>Muchowski</surname><given-names>PJ</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name><article-title>Accelerating amyloid-&#x003b2; fibrillization reduces oligomer levels and functional
deficits in Alzheimer disease mouse models</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>23818</fpage><lpage>23828</lpage><pub-id pub-id-type="doi">10.1074/jbc.M701078200</pub-id><pub-id pub-id-type="pmid">17548355</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Kotilinek</surname><given-names>L</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><article-title>Plaque-bearing mice with reduced levels of oligomeric amyloid-&#x003b2; assemblies
have intact memory function</article-title><source>Neurosci</source><year>2008</year><volume>151</volume><fpage>745</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.10.054</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>O&#x02019;Dell</surname><given-names>MA</given-names></name><name><surname>Taylor</surname><given-names>JW</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Cramer</surname><given-names>JW</given-names></name><name><surname>Audia</surname><given-names>JE</given-names></name><name><surname>Nissen</surname><given-names>JS</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title><italic>In vivo</italic> assessment of brain interstitial fluid with microdialysis reveals
plaque-associated changes in amyloid-&#x003b2; metabolism and half-life</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><fpage>8844</fpage><lpage>8853</lpage><pub-id pub-id-type="pmid">14523085</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Quintero-Monzon</surname><given-names>O</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Podlisny</surname><given-names>DR</given-names></name><name><surname>Cavanaugh</surname><given-names>WT</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Dynamic analysis of amyloid &#x003b2;-protein in behaving mice reveals opposing
changes in ISF vs. parenchymal A&#x003b2; during age-related plaque formation</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>15861</fpage><lpage>15869</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3272-11.2011</pub-id><pub-id pub-id-type="pmid">22049429</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Roe</surname><given-names>AD</given-names></name><name><surname>Hori</surname><given-names>Y</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><article-title>Brain interstitial oligomeric amyloid &#x003b2; increases with age and is resistant
to clearance from brain in a mouse model of Alzheimer&#x02019;s disease</article-title><source>FASEB J</source><year>2013</year><volume>27</volume><fpage>3239</fpage><lpage>3248</lpage><pub-id pub-id-type="doi">10.1096/fj.13-229666</pub-id><pub-id pub-id-type="pmid">23640054</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name><surname>Narayan</surname><given-names>P</given-names></name><name><surname>Ganzinger</surname><given-names>KA</given-names></name><name><surname>McColl</surname><given-names>J</given-names></name><name><surname>Weimann</surname><given-names>L</given-names></name><name><surname>Meehan</surname><given-names>S</given-names></name><name><surname>Qamar</surname><given-names>S</given-names></name><name><surname>Carver</surname><given-names>JA</given-names></name><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Klenerman</surname><given-names>D</given-names></name><article-title>Single molecule characterization of the interactions between amyloid-&#x003b2;
peptides and the membranes of hippocampal cells</article-title><source>J Am Chem Soc</source><year>2013</year><volume>135</volume><fpage>1491</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1021/ja3103567</pub-id><pub-id pub-id-type="pmid">23339742</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name><surname>Gravina</surname><given-names>SA</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Eckman</surname><given-names>CB</given-names></name><name><surname>Long</surname><given-names>KE</given-names></name><name><surname>Otvos</surname><given-names>L</given-names></name><name><surname>Younkin</surname><given-names>LH</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><article-title>Amyloid &#x003b2; protein (A&#x003b2;) in Alzheimer&#x02019;s disease brain: biochemical
and immunocytochemical analysis with antibodies specific for forms ending at
A&#x003b2;40 or A&#x003b2;42(43)</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>7013</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.13.7013</pub-id><pub-id pub-id-type="pmid">7706234</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name><surname>Wetzel</surname><given-names>R</given-names></name><article-title>Kinetics and thermodynamics of amyloid fibril assembly</article-title><source>Acc Chem Res</source><year>2006</year><volume>39</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1021/ar050069h</pub-id><pub-id pub-id-type="pmid">16981684</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name><surname>S&#x000e1;nchez</surname><given-names>L</given-names></name><name><surname>Madurga</surname><given-names>S</given-names></name><name><surname>Pukala</surname><given-names>T</given-names></name><name><surname>Vilaseca</surname><given-names>M</given-names></name><name><surname>L&#x000f3;pez-Iglesias</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>CV</given-names></name><name><surname>Giralt</surname><given-names>E</given-names></name><name><surname>Carulla</surname><given-names>N</given-names></name><article-title>A&#x003b2;40 and A&#x003b2;42 amyloid fibrils exhibit distinct molecular recycling
properties</article-title><source>J Am Chem Soc</source><year>2011</year><volume>133</volume><fpage>6505</fpage><lpage>6508</lpage><pub-id pub-id-type="doi">10.1021/ja1117123</pub-id><pub-id pub-id-type="pmid">21486030</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name><surname>Esler</surname><given-names>WP</given-names></name><name><surname>Stimson</surname><given-names>ER</given-names></name><name><surname>Jennings</surname><given-names>JM</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Ghilardi</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>JP</given-names></name><name><surname>Mantyh</surname><given-names>PW</given-names></name><name><surname>Maggio</surname><given-names>JE</given-names></name><article-title>Alzheimer&#x02019;s disease amyloid propagation by a template-dependent dock-lock
mechanism</article-title><source>Biochem</source><year>2000</year><volume>39</volume><fpage>6288</fpage><lpage>6295</lpage><pub-id pub-id-type="doi">10.1021/bi992933h</pub-id><pub-id pub-id-type="pmid">10828941</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name><surname>Koffie</surname><given-names>RM</given-names></name><name><surname>Mayer-Luehmann</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>KW</given-names></name><name><surname>Mielke</surname><given-names>ML</given-names></name><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>Micheva</surname><given-names>KD</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><article-title>Oligomeric amyloid &#x003b2; associates with postsynaptic densities and correlates
with excitatory synapse loss near senile plaques</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>4012</fpage><lpage>4017</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811698106</pub-id><pub-id pub-id-type="pmid">19228947</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name><surname>Atwood</surname><given-names>CA</given-names></name><name><surname>Obrenovich</surname><given-names>ME</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>H</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Martins</surname><given-names>RN</given-names></name><article-title>Amyloid-&#x003b2;: a chameleon walking in two worlds: a review of the trophic and
toxic properties of amyloid-&#x003b2;</article-title><source>Brain Res Rev</source><year>2003</year><volume>43</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0165-0173(03)00174-7</pub-id><pub-id pub-id-type="pmid">14499458</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name><surname>Giuffrida</surname><given-names>ML</given-names></name><name><surname>Caraci</surname><given-names>F</given-names></name><name><surname>Pagnataro</surname><given-names>B</given-names></name><name><surname>Cataldo</surname><given-names>S</given-names></name><name><surname>De Bona</surname><given-names>P</given-names></name><name><surname>Bruno</surname><given-names>V</given-names></name><name><surname>Molinaro</surname><given-names>G</given-names></name><name><surname>Pappalardo</surname><given-names>G</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Palmigiano</surname><given-names>A</given-names></name><name><surname>Garozzo</surname><given-names>D</given-names></name><name><surname>Nicoletti</surname><given-names>F</given-names></name><name><surname>Rizzarelli</surname><given-names>E</given-names></name><name><surname>Copani</surname><given-names>A</given-names></name><article-title>&#x003b2;-Amyloid monomers are neuroprotective</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>10582</fpage><lpage>10587</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1736-09.2009</pub-id><pub-id pub-id-type="pmid">19710311</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><name><surname>Baglioni</surname><given-names>S</given-names></name><name><surname>Casamenti</surname><given-names>F</given-names></name><name><surname>Bucciantini</surname><given-names>M</given-names></name><name><surname>Luheshi</surname><given-names>LM</given-names></name><name><surname>Taddei</surname><given-names>N</given-names></name><name><surname>Chiti</surname><given-names>F</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Stefani</surname><given-names>M</given-names></name><article-title>Prefibrillar amyloid aggregates could be generic toxins in higher organisms</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>8160</fpage><lpage>8162</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4809-05.2006</pub-id><pub-id pub-id-type="pmid">16885229</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><name><surname>Treusch</surname><given-names>S</given-names></name><name><surname>Cyr</surname><given-names>DM</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><article-title>Amyloid deposits: protection against toxic protein species?</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>1668</fpage><lpage>1674</lpage><pub-id pub-id-type="doi">10.4161/cc.8.11.8503</pub-id><pub-id pub-id-type="pmid">19411847</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><name><surname>Oda</surname><given-names>T</given-names></name><name><surname>Wals</surname><given-names>P</given-names></name><name><surname>Osterburg</surname><given-names>HH</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Pasinetti</surname><given-names>GM</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Rozovsky</surname><given-names>I</given-names></name><name><surname>Stine</surname><given-names>WB</given-names></name><name><surname>Snyder</surname><given-names>SW</given-names></name><name><surname>Holzman</surname><given-names>TF</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><article-title>Clusterin (apoJ) alters the aggregation of amyloid &#x003b2;-peptide (A&#x003b2;1-42)
and forms slowly sedimenting A&#x003b2; complexes that cause oxidative stress</article-title><source>Exp Neurobiol</source><year>1995</year><volume>136</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1006/exnr.1995.1080</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><name><surname>Standridge</surname><given-names>JB</given-names></name><article-title>Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer&#x02019;s
disease</article-title><source>Curr Alzheimers Res</source><year>2006</year><volume>3</volume><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.2174/156720506776383068</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><name><surname>Zemple</surname><given-names>H</given-names></name><name><surname>Thies</surname><given-names>E</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name><name><surname>Mandelkow</surname><given-names>EM</given-names></name><article-title>Abeta oligomers cause localized Ca<sup>2+</sup> elevation, missorting of
endogenous Tau into dendrites, Tau phosphorylation, and destruction of
microtubules and spines</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>11938</fpage><lpage>11950</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2357-10.2010</pub-id><pub-id pub-id-type="pmid">20826658</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><name><surname>Klyubin</surname><given-names>I</given-names></name><name><surname>Cullen</surname><given-names>WK</given-names></name><name><surname>Hu</surname><given-names>N-W</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><article-title>Alzheimer&#x02019;s disease A&#x003b2; assemblies mediating rapid disruption of
synaptic plasticity and memory</article-title><source>Molecular Brain</source><year>2012</year><volume>5</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1756-6606-5-25</pub-id><pub-id pub-id-type="pmid">22805374</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><name><surname>Kittelberger</surname><given-names>KA</given-names></name><name><surname>Piazza</surname><given-names>F</given-names></name><name><surname>Tesco</surname><given-names>G</given-names></name><name><surname>Reijmers</surname><given-names>LG</given-names></name><article-title>Natural amyloid-beta oligomers acutely impair the formation of a contextual fear
memory in mice</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e29940</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0029940</pub-id><pub-id pub-id-type="pmid">22238679</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><name><surname>Puzzo</surname><given-names>D</given-names></name><name><surname>Privitera</surname><given-names>L</given-names></name><name><surname>Leznik</surname><given-names>E</given-names></name><name><surname>F&#x000e0;</surname><given-names>M</given-names></name><name><surname>Staniszewski</surname><given-names>A</given-names></name><name><surname>Palmeri</surname><given-names>A</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><article-title>Picomolar amyloid-&#x003b2; positively modulates synaptic plasticity and memory in
hippocampus</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>14537</fpage><lpage>14545</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2692-08.2008</pub-id><pub-id pub-id-type="pmid">19118188</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><name><surname>Puzzo</surname><given-names>D</given-names></name><name><surname>Privitera</surname><given-names>L</given-names></name><name><surname>F&#x000e0;</surname><given-names>M</given-names></name><name><surname>Staniszewski</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>G</given-names></name><name><surname>Aziz</surname><given-names>F</given-names></name><name><surname>Sakurai</surname><given-names>M</given-names></name><name><surname>Ribe</surname><given-names>EM</given-names></name><name><surname>Troy</surname><given-names>CM</given-names></name><name><surname>Merchen</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>SS</given-names></name><name><surname>Palmeri</surname><given-names>A</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><article-title>Endogenous amyloid-&#x003b2; is necessary for hippocampal synaptic plasticity and
memory</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><fpage>819</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1002/ana.22313</pub-id><pub-id pub-id-type="pmid">21472769</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><name><surname>Puzzo</surname><given-names>D</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><article-title>Amyloid-&#x003b2; peptide: Dr. Jekyll or Mr. Hyde?</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>33</volume><fpage>S111</fpage><lpage>S120</lpage><pub-id pub-id-type="pmid">22735675</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Buniel</surname><given-names>MC</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Fernandez</surname><given-names>SJ</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>Synaptic targeting by Alzheimer&#x02019;s-related amyloid &#x003b2; oligomers</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>10191</fpage><lpage>10200</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3432-04.2004</pub-id><pub-id pub-id-type="pmid">15537891</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Buniel</surname><given-names>MC</given-names></name><name><surname>Furlow</surname><given-names>PW</given-names></name><name><surname>Clemente</surname><given-names>AS</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>A&#x003b2; oligomer-induced aberrations in synapse composition, shape, and density
provide a molecular basis for loss of connectivity in Alzheimer&#x02019;s
disease</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>796</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3501-06.2007</pub-id><pub-id pub-id-type="pmid">17251419</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><name><surname>Shughrue</surname><given-names>PJ</given-names></name><name><surname>Acton</surname><given-names>PJ</given-names></name><name><surname>Breese</surname><given-names>RS</given-names></name><name><surname>Zhao</surname><given-names>W-Q</given-names></name><name><surname>Chen-Dodson</surname><given-names>E</given-names></name><name><surname>Hepler</surname><given-names>RW</given-names></name><name><surname>Wolfe</surname><given-names>AL</given-names></name><name><surname>Matthews</surname><given-names>M</given-names></name><name><surname>Heidecker</surname><given-names>GJ</given-names></name><name><surname>Joyce</surname><given-names>JG</given-names></name><name><surname>Villarreal</surname><given-names>SA</given-names></name><name><surname>Kinney</surname><given-names>JJ</given-names></name><article-title>Anti-ADDL antibodies differentially block oligomer binding to hippocampal
neurons</article-title><source>Neurobiol Aging</source><year>2010</year><volume>31</volume><fpage>189</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2008.04.003</pub-id><pub-id pub-id-type="pmid">18486276</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><name><surname>Rammes</surname><given-names>G</given-names></name><name><surname>Hasenjager</surname><given-names>A</given-names></name><name><surname>Sroka-Saidi</surname><given-names>K</given-names></name><name><surname>Deussing</surname><given-names>JM</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><article-title>Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic
glutamate receptors in mediating the synaptotoxic effects of &#x003b2;-amyloid
oligomers on long-term potentiation (LTP) in murine hippocampal slices</article-title><source>Neuropharmacology</source><year>2011</year><volume>60</volume><fpage>982</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.051</pub-id><pub-id pub-id-type="pmid">21310164</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><name><surname>Poling</surname><given-names>A</given-names></name><name><surname>Paisley-Morgan</surname><given-names>K</given-names></name><name><surname>Panos</surname><given-names>JJ</given-names></name><name><surname>Kim</surname><given-names>E-M</given-names></name><name><surname>O&#x02019;Hare</surname><given-names>E</given-names></name><name><surname>Cleary</surname><given-names>JP</given-names></name><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><name><surname>Porritt</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>L</given-names></name><article-title>Oligomers of the amyloid-beta protein disrupt working memory: confirmation with
two behavioral procedures</article-title><source>Behav Brain Res</source><year>2008</year><volume>193</volume><fpage>230</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2008.06.001</pub-id><pub-id pub-id-type="pmid">18585407</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><name><surname>De Felice</surname><given-names>FG</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Fernandez</surname><given-names>SJ</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Jerecic</surname><given-names>J</given-names></name><name><surname>Acton</surname><given-names>PJ</given-names></name><name><surname>Shughrue</surname><given-names>PJ</given-names></name><name><surname>Chen-Dodson</surname><given-names>E</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>Alzheimer&#x02019;s disease-type neuronal tau hyperphosphorylation induced by
A&#x003b2; oligomers</article-title><source>Neurobiol Aging</source><year>2008</year><volume>29</volume><fpage>1334</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.02.029</pub-id><pub-id pub-id-type="pmid">17403556</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Shepardson</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Walsh</surname><given-names>D</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Soluble amyloid &#x003b2;-protein dimers isolated from Alzheimer cortex directly
induce Tau hyperphosphorylation and neuritic degeneration</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>5819</fpage><lpage>5824</lpage><pub-id pub-id-type="doi">10.1073/pnas.1017033108</pub-id><pub-id pub-id-type="pmid">21421841</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><name><surname>Chabrier</surname><given-names>MA</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name><name><surname>Agazaryan</surname><given-names>AA</given-names></name><name><surname>Nerhus</surname><given-names>JL</given-names></name><name><surname>Martinez-Coria</surname><given-names>H</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name><article-title>Soluble A&#x003b2; promotes wild-type tau pathology <italic>in vivo</italic></article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>17345</fpage><lpage>17350</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0172-12.2012</pub-id><pub-id pub-id-type="pmid">23197725</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><name><surname>Oddo</surname><given-names>S</given-names></name><name><surname>Caccamo</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name><article-title>Temporal profile of amyloid-&#x003b2; (A&#x003b2;) oligomerization in an <italic>in
vivo</italic> model of Alzheimer disease: a link between A&#x003b2; and tau
pathology</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>1599</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1074/jbc.M507892200</pub-id><pub-id pub-id-type="pmid">16282321</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><name><surname>Small</surname><given-names>SA</given-names></name><name><surname>Duff</surname><given-names>K</given-names></name><article-title>Linking A&#x003b2; and tau in late-onset Alzheimer&#x02019;s disease: a dual pathway
hypothesis</article-title><source>Neuron</source><year>2008</year><volume>60</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.11.007</pub-id><pub-id pub-id-type="pmid">19038212</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><name><surname>Zempel</surname><given-names>H</given-names></name><name><surname>Luedtke</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>Y</given-names></name><name><surname>Biernat</surname><given-names>J</given-names></name><name><surname>Dawson</surname><given-names>H</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name><name><surname>Kandelkow</surname><given-names>E-M</given-names></name><article-title>Amyloid-&#x003b2; oligomers induce synaptic damage via Tau-dependent microtubule
severing by TTLL6 and spastin</article-title><source>EMBO J</source><year>2013</year><volume>32</volume><fpage>2920</fpage><lpage>2937</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.207</pub-id><pub-id pub-id-type="pmid">24065130</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Emmerling</surname><given-names>MR</given-names></name><name><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name><surname>Kasunic</surname><given-names>TC</given-names></name><name><surname>Kirkpatrick</surname><given-names>JB</given-names></name><name><surname>Murdoch</surname><given-names>GH</given-names></name><name><surname>Ball</surname><given-names>MJ</given-names></name><name><surname>Roher</surname><given-names>AE</given-names></name><article-title>Water-soluble A&#x003b2; (N-40, N-42) oligomers in normal and Alzheimer&#x02019;s
disease brains</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>4077</fpage><lpage>4081</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.8.4077</pub-id><pub-id pub-id-type="pmid">8626743</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>Alzheimer&#x02019;s disease-affected brain: presence of oligomeric A&#x003b2; ligands
(ADDLs) suggests a molecular basis for reversible memory loss</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>10417</fpage><lpage>10422</lpage><pub-id pub-id-type="doi">10.1073/pnas.1834302100</pub-id><pub-id pub-id-type="pmid">12925731</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><name><surname>Sehlin</surname><given-names>D</given-names></name><name><surname>Englund</surname><given-names>H</given-names></name><name><surname>Simu</surname><given-names>B</given-names></name><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Nikolajeff</surname><given-names>F</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Pettersson</surname><given-names>FE</given-names></name><article-title>Large aggregates are the major soluble A&#x003b2; species in AD brain fractionated
with density gradient ultracentrifugation</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e32014</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0032014</pub-id><pub-id pub-id-type="pmid">22355408</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><name><surname>Georganopoulou</surname><given-names>DG</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Nam</surname><given-names>J-M</given-names></name><name><surname>Thaxton</surname><given-names>SC</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Mirkin</surname><given-names>CA</given-names></name><article-title>Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic
biomarker for Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>2273</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409336102</pub-id><pub-id pub-id-type="pmid">15695586</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>CM</given-names></name><name><surname>Yam</surname><given-names>AY</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Magdangal</surname><given-names>E</given-names></name><name><surname>Salisbury</surname><given-names>C</given-names></name><name><surname>Peretz</surname><given-names>D</given-names></name><name><surname>Zuckermann</surname><given-names>RN</given-names></name><name><surname>Connolly</surname><given-names>MD</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Fedynyshyn</surname><given-names>JP</given-names></name><name><surname>Allauzen</surname><given-names>S</given-names></name><article-title>A&#x003b2;40 oligomers identified as a potential biomarker for the diagnosis of
Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e15725</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0015725</pub-id><pub-id pub-id-type="pmid">21209907</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>AN</given-names></name><name><surname>Ewers</surname><given-names>M</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Simm</surname><given-names>A</given-names></name><name><surname>Silber</surname><given-names>R-E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Prvulovic</surname><given-names>D</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><article-title>Amyloid-&#x003b2; oligomers in cerebrospinal fluid are associated with cognitive
decline in patients with Alzheimer&#x02019;s disease</article-title><source>J Alzheimer&#x02019;s Dis</source><year>2012</year><volume>29</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">22214781</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><name><surname>Esparza</surname><given-names>TJ</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Brody</surname><given-names>DL</given-names></name><article-title>Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology
controls</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>104</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1002/ana.23748</pub-id><pub-id pub-id-type="pmid">23225543</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><name><surname>Herskovits</surname><given-names>AZ</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><article-title>A luminex assay detects amyloid &#x003b2; oligomers in Alzheimer&#x02019;s disease
cerebrospinal fluid</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e67898</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0067898</pub-id><pub-id pub-id-type="pmid">23844122</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><name><surname>Glabe</surname><given-names>CG</given-names></name><article-title>Structural classification of toxic amyloid oligomers</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>29639</fpage><lpage>29643</lpage><pub-id pub-id-type="doi">10.1074/jbc.R800016200</pub-id><pub-id pub-id-type="pmid">18723507</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><name><surname>Rahimi</surname><given-names>F</given-names></name><name><surname>Shanmugam</surname><given-names>A</given-names></name><name><surname>Bitan</surname><given-names>G</given-names></name><article-title>Structure-function relationships of pre-fibrillar protein assemblies in
Alzheimer&#x02019;s disease and related disorders</article-title><source>Curr Alzheimer Res</source><year>2008</year><volume>5</volume><fpage>319</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.2174/156720508784533358</pub-id><pub-id pub-id-type="pmid">18537546</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><name><surname>F&#x000e4;ndrich</surname><given-names>M</given-names></name><article-title>Oligomeric intermediates in amyloid formation: structure determination and
mechanisms of toxicity</article-title><source>J Mol Biol</source><year>2012</year><volume>421</volume><fpage>427</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2012.01.006</pub-id><pub-id pub-id-type="pmid">22248587</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><name><surname>Roher</surname><given-names>AE</given-names></name><name><surname>Chaney</surname><given-names>MO</given-names></name><name><surname>Kuo</surname><given-names>Y-M</given-names></name><name><surname>Webster</surname><given-names>SD</given-names></name><name><surname>Stine</surname><given-names>WB</given-names></name><name><surname>Haverkamp</surname><given-names>LJ</given-names></name><name><surname>Woods</surname><given-names>AS</given-names></name><name><surname>Cotter</surname><given-names>RJ</given-names></name><name><surname>Tuohy</surname><given-names>JM</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Bonnell</surname><given-names>BS</given-names></name><name><surname>Emmerling</surname><given-names>MR</given-names></name><article-title>Morphology and toxicity of A&#x003b2;-(1-42) dimer derived from neuritic and vascular
amyloid deposits of Alzheimer&#x02019;s disease</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>20631</fpage><lpage>20635</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.34.20631</pub-id><pub-id pub-id-type="pmid">8702810</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>N-W</given-names></name><name><surname>Smith</surname><given-names>IM</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><article-title>Soluble amyloid-&#x003b2; peptides potently disrupt hippocampal synaptic plasticity
in the absence of cerebrovascular dysfunction <italic>in vivo</italic></article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>2414</fpage><lpage>2424</lpage><pub-id pub-id-type="doi">10.1093/brain/awn174</pub-id><pub-id pub-id-type="pmid">18678563</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Ye</surname><given-names>CP</given-names></name><name><surname>Diehl</surname><given-names>T</given-names></name><name><surname>Vasquez</surname><given-names>S</given-names></name><name><surname>Vassilev</surname><given-names>PM</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Protofibrillar intermediates of amyloid &#x003b2;-protein induce acute
electrophysiological changes and progressive neurotoxicity in cortical neurons</article-title><source>J Neurosci</source><year>1999</year><volume>19</volume><fpage>8876</fpage><lpage>8884</lpage><pub-id pub-id-type="pmid">10516307</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Garzon</surname><given-names>DJ</given-names></name><name><surname>Marchese</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>W</given-names></name><name><surname>Ginsberg</surname><given-names>SD</given-names></name><name><surname>Francis</surname><given-names>BM</given-names></name><name><surname>Mount</surname><given-names>HT</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Salehi</surname><given-names>A</given-names></name><name><surname>Fahnestock</surname><given-names>M</given-names></name><article-title>Decreased brain-derived neurotrophic factor depends on amyloid aggregation state
in transgenic mouse models of Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>9321</fpage><lpage>9329</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4736-08.2009</pub-id><pub-id pub-id-type="pmid">19625522</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><name><surname>Chromy</surname><given-names>BA</given-names></name><name><surname>Nowak</surname><given-names>RJ</given-names></name><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Jones</surname><given-names>BW</given-names></name><name><surname>Fernandez</surname><given-names>SJ</given-names></name><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Horowitz</surname><given-names>P</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>Self-assembly of A&#x003b2;1-42 into globular neurotoxins</article-title><source>Biochem</source><year>2003</year><volume>42</volume><fpage>12749</fpage><lpage>12760</lpage><pub-id pub-id-type="doi">10.1021/bi030029q</pub-id><pub-id pub-id-type="pmid">14596589</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Structure-neurotoxicity relationships of amyloid &#x003b2;-protein oligomers</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>14745</fpage><lpage>14750</lpage><pub-id pub-id-type="doi">10.1073/pnas.0905127106</pub-id><pub-id pub-id-type="pmid">19706468</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><name><surname>R&#x000f6;nicke</surname><given-names>R</given-names></name><name><surname>Klemm</surname><given-names>A</given-names></name><name><surname>Meinhardt</surname><given-names>J</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>UH</given-names></name><name><surname>F&#x000e4;ndrich</surname><given-names>M</given-names></name><name><surname>Reymann</surname><given-names>KG</given-names></name><article-title>A&#x003b2; mediated diminution of MMT reduction - an artefact of single cell
culture?</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e3236</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0003236</pub-id><pub-id pub-id-type="pmid">18800168</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><name><surname>Podlisny</surname><given-names>MB</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Amarante</surname><given-names>P</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Stimson</surname><given-names>ER</given-names></name><name><surname>Maggio</surname><given-names>JE</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Oligomerization of endogenous and synthetic amyloid &#x003b2;-protein at nanomolar
levels in cell culture and stabilization of monomer by Congo red</article-title><source>Biochemistry</source><year>1998</year><volume>37</volume><fpage>3602</fpage><lpage>3611</lpage><pub-id pub-id-type="doi">10.1021/bi972029u</pub-id><pub-id pub-id-type="pmid">9521679</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Klyubin</surname><given-names>I</given-names></name><name><surname>Fadeeva</surname><given-names>JV</given-names></name><name><surname>Cullen</surname><given-names>WK</given-names></name><name><surname>Anwyl</surname><given-names>R</given-names></name><name><surname>Wolfe</surname><given-names>MS</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Naturally secreted oligomers of amyloid &#x003b2; protein potently inhibit
hippocampal long-term potentiation <italic>in vivo</italic></article-title><source>Nature</source><year>2002</year><volume>416</volume><fpage>535</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1038/416535a</pub-id><pub-id pub-id-type="pmid">11932745</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Podlisny</surname><given-names>MB</given-names></name><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Fadeeva</surname><given-names>JV</given-names></name><name><surname>Agnaf</surname><given-names>OE</given-names></name><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Certain inhibitors of synthetic amyloid &#x003b2;-peptide (A&#x003b2;) fibrillogenesis
block oligomerization of natural A&#x003b2; and thereby rescue long-term
potentiation</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>2455</fpage><lpage>2462</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4391-04.2005</pub-id><pub-id pub-id-type="pmid">15758153</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><name><surname>Bitan</surname><given-names>G</given-names></name><name><surname>Fradinger</surname><given-names>EA</given-names></name><name><surname>Spring</surname><given-names>SM</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><article-title>Neurotoxic protein oligomers - what you see is not always what you get</article-title><source>Amyloid</source><year>2005</year><volume>12</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1080/13506120500106958</pub-id><pub-id pub-id-type="pmid">16011984</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><name><surname>Kimura</surname><given-names>R</given-names></name><name><surname>MacTavish</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Westaway</surname><given-names>D</given-names></name><name><surname>Jhamandas</surname><given-names>JH</given-names></name><article-title>Beta amyloid-induced depression of hippocampal long-term potentiation is mediated
through the amylin receptor</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>17401</fpage><lpage>17406</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3028-12.2012</pub-id><pub-id pub-id-type="pmid">23197731</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Bloodgood</surname><given-names>BL</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name><article-title>Natural oligomers of the Alzheimer amyloid-&#x003b2; protein induce reversible
synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling
pathway</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>2866</fpage><lpage>2875</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4970-06.2007</pub-id><pub-id pub-id-type="pmid">17360908</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Shepardson</surname><given-names>NE</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name><article-title>Soluble oligomers of amyloid &#x003b2; protein facilitate hippocampal long-term
depression by disrupting neuronal glutamate uptake</article-title><source>Neuron</source><year>2009</year><volume>62</volume><fpage>788</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.05.012</pub-id><pub-id pub-id-type="pmid">19555648</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>LN</given-names></name><name><surname>Kessels</surname><given-names>HW</given-names></name><name><surname>Hagiwara</surname><given-names>H</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name><article-title>Amyloid beta from axons and dendrites reduces local spine number and
plasticity</article-title><source>Nat Neurosci</source><year>2010</year><volume>13</volume><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nn.2476</pub-id><pub-id pub-id-type="pmid">20037574</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><name><surname>Tamburri</surname><given-names>A</given-names></name><name><surname>Dudilot</surname><given-names>A</given-names></name><name><surname>Licea</surname><given-names>S</given-names></name><name><surname>Bourgeois</surname><given-names>C</given-names></name><name><surname>Boehm</surname><given-names>J</given-names></name><article-title>NMDA-receptor activation but not ion flux is required for amyloid-beta induced
synaptic depression</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e65350</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0065350</pub-id><pub-id pub-id-type="pmid">23750255</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><name><surname>Malinow</surname><given-names>R</given-names></name><article-title>New developments on the role of NMDA receptors in Alzheimer&#x02019;s disease</article-title><source>Curr Opin Neurobiol</source><year>2012</year><volume>22</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2011.09.001</pub-id><pub-id pub-id-type="pmid">21962484</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><name><surname>Takamura</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Watabe</surname><given-names>D</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Nakata</surname><given-names>T</given-names></name><name><surname>Kawarabayashi</surname><given-names>T</given-names></name><name><surname>Oddo</surname><given-names>S</given-names></name><name><surname>Laferla</surname><given-names>FM</given-names></name><name><surname>Shoji</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>E</given-names></name><article-title>Sortilin is required for toxic action of A&#x003b2; oligomers (A&#x003b2;Os):
extracellular A&#x003b2;Os trigger apoptosis, and intraneuronal A&#x003b2;Os impair
degradation pathways</article-title><source>Life Sci</source><year>2012</year><volume>91</volume><fpage>1177</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2012.04.038</pub-id><pub-id pub-id-type="pmid">22579764</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>McLaughlin</surname><given-names>R</given-names></name><name><surname>Goodyer</surname><given-names>C</given-names></name><name><surname>LeBlanc</surname><given-names>A</given-names></name><article-title>Selective cytotoxicity of intracellular amyloid &#x003b2; peptide<sub>1-42</sub>
through p53 and Bax in cultured primary human neurons</article-title><source>J Cell Biol</source><year>2002</year><volume>156</volume><fpage>519</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1083/jcb.200110119</pub-id><pub-id pub-id-type="pmid">11815632</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><name><surname>Vitolo</surname><given-names>OV</given-names></name><name><surname>Sant&#x02019;Angelo</surname><given-names>A</given-names></name><name><surname>Costanzo</surname><given-names>V</given-names></name><name><surname>Battaglia</surname><given-names>F</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Shelanski</surname><given-names>M</given-names></name><article-title>Amyloid &#x003b2;-peptide inhibition of the PKA/CREB pathway and long-term
potentiation: reversibility by drugs that enhance cAMP signaling</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>13217</fpage><lpage>13221</lpage><pub-id pub-id-type="doi">10.1073/pnas.172504199</pub-id><pub-id pub-id-type="pmid">12244210</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Pozueta</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>B</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Shelanski</surname><given-names>M</given-names></name><article-title>Reversal of long-term dendritic spine alterations in Alzheimer disease models</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>16877</fpage><lpage>16882</lpage><pub-id pub-id-type="doi">10.1073/pnas.0908706106</pub-id><pub-id pub-id-type="pmid">19805389</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Anwyl</surname><given-names>R</given-names></name><article-title>Block of long-term potentiation by naturally secreted and synthetic amyloid
&#x003b2;-peptide in hippocampal slices is mediated via activation of the kinases
c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated
protein kinase as well as metabotropic glutamate receptor type 5</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>3370</fpage><lpage>3378</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1633-03.2004</pub-id><pub-id pub-id-type="pmid">15056716</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><name><surname>Tsigelny</surname><given-names>IF</given-names></name><name><surname>Crews</surname><given-names>L</given-names></name><name><surname>Desplats</surname><given-names>P</given-names></name><name><surname>Shaked</surname><given-names>GM</given-names></name><name><surname>Sharikov</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Spencer</surname><given-names>B</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Trejo</surname><given-names>M</given-names></name><name><surname>Platoshyn</surname><given-names>O</given-names></name><name><surname>Yuan</surname><given-names>JX-J</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>Mechanisms of hybrid oligomer formation in the pathogenesis of combined
Alzheimer&#x02019;s and Parkinson&#x02019;s diseases</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e3135</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0003135</pub-id><pub-id pub-id-type="pmid">18769546</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><name><surname>Cisse</surname><given-names>M</given-names></name><name><surname>Halabisky</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Devidze</surname><given-names>N</given-names></name><name><surname>Dubal</surname><given-names>DB</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Orr</surname><given-names>A</given-names></name><name><surname>Lotz</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Hamto</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>G-Q</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name><article-title>Reversing EphB2 depletion rescues cognitive functions in Alzheimer model</article-title><source>Nature</source><year>2011</year><volume>469</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/nature09635</pub-id><pub-id pub-id-type="pmid">21113149</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Nwabuisi-Heath</surname><given-names>E</given-names></name><name><surname>Laxton</surname><given-names>K</given-names></name><name><surname>LaDu</surname><given-names>MJ</given-names></name><article-title>Endocytic pathways mediating oligomeric A&#x003b2;42 neurotoxicity</article-title><source>Mol Neurodegener</source><year>2010</year><volume>5</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-5-19</pub-id><pub-id pub-id-type="pmid">20478062</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><name><surname>Renner</surname><given-names>M</given-names></name><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Contractor</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Triller</surname><given-names>A</given-names></name><article-title>Deleterious effects of amyloid &#x003b2; oligomers acting as an extracellular
scaffold for mGluR5</article-title><source>Neuron</source><year>2010</year><volume>66</volume><fpage>739</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.04.029</pub-id><pub-id pub-id-type="pmid">20547131</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><name><surname>Um</surname><given-names>JW</given-names></name><name><surname>Kaufman</surname><given-names>AC</given-names></name><name><surname>Kostylev</surname><given-names>M</given-names></name><name><surname>Heiss</surname><given-names>JK</given-names></name><name><surname>Stagi</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kerrisk</surname><given-names>ME</given-names></name><name><surname>Vortmeyer</surname><given-names>A</given-names></name><name><surname>Wisniewski</surname><given-names>T</given-names></name><name><surname>Koleske</surname><given-names>AJ</given-names></name><name><surname>Gunther</surname><given-names>EC</given-names></name><name><surname>Nygaard</surname><given-names>HB</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name><article-title>Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer A&#x003b2; oligomer
bound to cellular prion protein</article-title><source>Neuron</source><year>2013</year><volume>79</volume><fpage>887</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.06.036</pub-id><pub-id pub-id-type="pmid">24012003</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><name><surname>Paranjape</surname><given-names>GS</given-names></name><name><surname>Gouwens</surname><given-names>LK</given-names></name><name><surname>Osborn</surname><given-names>DC</given-names></name><name><surname>Nishols</surname><given-names>MR</given-names></name><article-title>Isolated amyloid(1-42) protofibrils, but not isolated fibrils, are robust
stimulators of microglia</article-title><source>ACS Chem Neurosci</source><year>2012</year><volume>3</volume><fpage>302</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1021/cn2001238</pub-id><pub-id pub-id-type="pmid">22860196</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><name><surname>Ostapchenko</surname><given-names>VG</given-names></name><name><surname>Beraldo</surname><given-names>FH</given-names></name><name><surname>Mohammad</surname><given-names>AH</given-names></name><name><surname>Xie</surname><given-names>Y-F</given-names></name><name><surname>Hirata</surname><given-names>PHF</given-names></name><name><surname>Magalhaes</surname><given-names>AC</given-names></name><name><surname>Lamour</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Maciejewski</surname><given-names>A</given-names></name><name><surname>Belrose</surname><given-names>JC</given-names></name><name><surname>Teixeira</surname><given-names>BL</given-names></name><name><surname>Fahnestock</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>ST</given-names></name><name><surname>Cashman</surname><given-names>NR</given-names></name><name><surname>Hajj</surname><given-names>GNM</given-names></name><name><surname>Jackson</surname><given-names>MF</given-names></name><name><surname>Choy</surname><given-names>W-Y</given-names></name><name><surname>MacDonald</surname><given-names>JF</given-names></name><name><surname>Martins</surname><given-names>VR</given-names></name><name><surname>Prado</surname><given-names>VF</given-names></name><name><surname>Prado</surname><given-names>MAM</given-names></name><article-title>The prion protein ligand, stress-inducible phosphoprotein 1, regulates
amyloid-&#x003b2; oligomer toxicity</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>16552</fpage><lpage>16564</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3214-13.2013</pub-id><pub-id pub-id-type="pmid">24133259</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><name><surname>Younan</surname><given-names>ND</given-names></name><name><surname>Sarell</surname><given-names>CJ</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Viles</surname><given-names>JH</given-names></name><article-title>The cellular prion protein traps Alzheimer&#x02019;s A&#x003b2; in an oligomeric form
and disassembles amyloid fibers</article-title><source>FASEB J</source><year>2013</year><volume>27</volume><fpage>1847</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1096/fj.12-222588</pub-id><pub-id pub-id-type="pmid">23335053</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><name><surname>Um</surname><given-names>JW</given-names></name><name><surname>Nygaard</surname><given-names>HB</given-names></name><name><surname>Heiss</surname><given-names>JK</given-names></name><name><surname>Kostylev</surname><given-names>MA</given-names></name><name><surname>Stagi</surname><given-names>M</given-names></name><name><surname>Vortmeyer</surname><given-names>A</given-names></name><name><surname>Wisniewski</surname><given-names>T</given-names></name><name><surname>Gunther</surname><given-names>EC</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name><article-title>Alzheimer amyloid-&#x003b2; oligomer bound to post-synaptic prion protein activates
Fyn to impair neurons</article-title><source>Nat Neurosci</source><year>2012</year><volume>15</volume><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1038/nn.3178</pub-id><pub-id pub-id-type="pmid">22820466</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><name><surname>Larson</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>MA</given-names></name><name><surname>Amar</surname><given-names>F</given-names></name><name><surname>Nuvolone</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Lesn&#x000e9;</surname><given-names>SE</given-names></name><article-title>The complex PrP<sup>c</sup>-Fyn couples human oligomeric A&#x003b2; with pathological
tau changes in Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>16857</fpage><lpage>16871</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1858-12.2012</pub-id><pub-id pub-id-type="pmid">23175838</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>W-Q</given-names></name><name><surname>Santini</surname><given-names>F</given-names></name><name><surname>Breese</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>XD</given-names></name><name><surname>Stone</surname><given-names>DJ</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Wolfe</surname><given-names>AL</given-names></name><name><surname>Seager</surname><given-names>MA</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><name><surname>Shughrue</surname><given-names>PJ</given-names></name><name><surname>Ray</surname><given-names>WJ</given-names></name><article-title>Inhibition of calcineurin-mediated endocytosis and
&#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptors
prevents amyloid &#x003b2; oligomer-induced synaptic disruption</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>7619</fpage><lpage>7632</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.057182</pub-id><pub-id pub-id-type="pmid">20032460</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>H-Y</given-names></name><name><surname>Hudry</surname><given-names>E</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Kuchibhotla</surname><given-names>K</given-names></name><name><surname>Rozkalne</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Spires-Jones</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Arbel-Ornath</surname><given-names>M</given-names></name><name><surname>Grosskreutz</surname><given-names>CL</given-names></name><name><surname>Bacskai</surname><given-names>BJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><article-title>Amyloid &#x003b2; induces the morphological neurodegenerative triad of spine loss,
dendritic simplification, and neuritic dystrophies through calcineurin
activation</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>2636</fpage><lpage>2649</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4456-09.2010</pub-id><pub-id pub-id-type="pmid">20164348</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>H-Y</given-names></name><name><surname>Hudry</surname><given-names>E</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>Z-Y</given-names></name><name><surname>Berezovska</surname><given-names>O</given-names></name><name><surname>Grosskreutz</surname><given-names>CL</given-names></name><name><surname>Bacskai</surname><given-names>BJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><article-title>Distinct dendritic spine and nuclear phases of calcineurin activation after
exposure to amyloid-&#x003b2; revealed by a novel fluorescence resonance energy
transfer assay</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>5298</fpage><lpage>5309</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0227-12.2012</pub-id><pub-id pub-id-type="pmid">22496575</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Vidal</surname><given-names>GS</given-names></name><name><surname>Djurisic</surname><given-names>M</given-names></name><name><surname>William</surname><given-names>CM</given-names></name><name><surname>Birnbaum</surname><given-names>ME</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Shatz</surname><given-names>CJ</given-names></name><article-title>Human LilrB2 is a &#x003b2;-amyloid receptor and its murine homolog PirB regulates
synaptic plasticity in an Alzheimer&#x02019;s model</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>1399</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1126/science.1242077</pub-id><pub-id pub-id-type="pmid">24052308</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>T</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Soluble A&#x003b2; inhibits specific signal transduction cascades common to the
insulin receptor pathway</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>33305</fpage><lpage>33312</lpage><pub-id pub-id-type="doi">10.1074/jbc.M610390200</pub-id><pub-id pub-id-type="pmid">17855343</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="other"><name><surname>Catalano</surname><given-names>SM</given-names></name><name><surname>Rishton</surname><given-names>G</given-names></name><name><surname>Izzo</surname><given-names>NJ</given-names></name><source>Compositions and methods for treating neurodegenerative disease</source><series>International Patent Publication Number, WO 2013/029060 A2</series><year>2013</year></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><name><surname>Benilova</surname><given-names>I</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><article-title>Promiscuous Alzheimer&#x02019;s amyloid: yet another partner</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>1354</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1126/science.1244166</pub-id><pub-id pub-id-type="pmid">24052299</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><name><surname>Teblow</surname><given-names>DB</given-names></name><article-title>On the subject of rigor in the study of amyloid &#x003b2;-protein assembly</article-title><source>Alzheimers Res Ther</source><year>2013</year><volume>5</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/alzrt203</pub-id><pub-id pub-id-type="pmid">23981712</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><name><surname>Stine</surname><given-names>WB</given-names></name><name><surname>Jungbauer</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>LaDu</surname><given-names>MJ</given-names></name><article-title>Preparing synthetic A&#x003b2; in different aggregation states</article-title><source>Methods Mol Biol</source><year>2011</year><volume>670</volume><fpage>13</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">20967580</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>DA</given-names></name><name><surname>Narrow</surname><given-names>WC</given-names></name><name><surname>Federoff</surname><given-names>HJ</given-names></name><name><surname>Bowers</surname><given-names>WJ</given-names></name><article-title>An improved method of generating consistent soluble amyloid-beta oligomer
preparations for <italic>in vitro</italic> neurotoxicity studies</article-title><source>J Neurosci Methods</source><year>2010</year><volume>190</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2010.05.001</pub-id><pub-id pub-id-type="pmid">20452375</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><name><surname>Zago</surname><given-names>W</given-names></name><name><surname>Buttini</surname><given-names>M</given-names></name><name><surname>Comery</surname><given-names>TA</given-names></name><name><surname>Nishioka</surname><given-names>C</given-names></name><name><surname>Gardai</surname><given-names>SJ</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><article-title>Neutralization of soluble, synaptotoxic amyloid &#x003b2; species by antibodies is
epitope specific</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>2696</fpage><lpage>2702</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1676-11.2012</pub-id><pub-id pub-id-type="pmid">22357853</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>YJ</given-names></name><name><surname>Watts</surname><given-names>RJ</given-names></name><article-title>Developing therapeutic antibodies for neurodegenerative disease</article-title><source>Neurotherapeutics</source><year>2013</year><volume>10</volume><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1007/s13311-013-0187-4</pub-id><pub-id pub-id-type="pmid">23549647</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Aucoin</surname><given-names>D</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Ahuja</surname><given-names>S</given-names></name><name><surname>Aimoto</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>JI</given-names></name><name><surname>Van Nostrand</surname><given-names>WE</given-names></name><name><surname>Smith</surname><given-names>SO</given-names></name><article-title>Structural conversion of neurotoxic amyloid-&#x003b2;(1-42) oligomers to fibrils</article-title><source>Nat Struct Mol Biol</source><year>2010</year><volume>17</volume><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1799</pub-id><pub-id pub-id-type="pmid">20383142</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><name><surname>Chaney</surname><given-names>MO</given-names></name><name><surname>Webster</surname><given-names>SD</given-names></name><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Foher</surname><given-names>AF</given-names></name><article-title>Molecular modeling of the A&#x003b2;1-42 peptide from Alzheimer&#x02019;s disease</article-title><source>Protein Eng</source><year>1998</year><volume>11</volume><fpage>761</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1093/protein/11.9.761</pub-id><pub-id pub-id-type="pmid">9796824</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><name><surname>Mastrangelo</surname><given-names>IA</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Hough</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>SO</given-names></name><article-title>High-resolution atomic force microscopy of soluble A&#x003b2;42 oligomers</article-title><source>J Mol Biol</source><year>2006</year><volume>358</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.01.042</pub-id><pub-id pub-id-type="pmid">16499926</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><name><surname>Cerf</surname><given-names>E</given-names></name><name><surname>Sarroukh</surname><given-names>R</given-names></name><name><surname>Tamamizu-Kato</surname><given-names>S</given-names></name><name><surname>Breydo</surname><given-names>L</given-names></name><name><surname>Derclaye</surname><given-names>S</given-names></name><name><surname>Dufr&#x000ea;ne</surname><given-names>YF</given-names></name><name><surname>Narayanaswami</surname><given-names>V</given-names></name><name><surname>Goormaghtigh</surname><given-names>E</given-names></name><name><surname>Ruysschaert</surname><given-names>J-M</given-names></name><name><surname>Raussens</surname><given-names>V</given-names></name><article-title>Antiparallel &#x003b2;-sheet: a signature structure of the oligomeric amyloid
&#x003b2;-peptide</article-title><source>Biochem J</source><year>2009</year><volume>421</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1042/BJ20090379</pub-id><pub-id pub-id-type="pmid">19435461</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><name><surname>Hillen</surname><given-names>H</given-names></name><name><surname>Barghorn</surname><given-names>S</given-names></name><name><surname>Striebinger</surname><given-names>A</given-names></name><name><surname>Labkovsky</surname><given-names>B</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name><name><surname>Nimmrich</surname><given-names>V</given-names></name><name><surname>Nolte</surname><given-names>MW</given-names></name><name><surname>Perez-Cruz</surname><given-names>C</given-names></name><name><surname>van der Auwera</surname><given-names>I</given-names></name><name><surname>van Leuven</surname><given-names>F</given-names></name><name><surname>van Gaalen</surname><given-names>M</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name><name><surname>Schoemaker</surname><given-names>H</given-names></name><name><surname>Sullivan</surname><given-names>JP</given-names></name><name><surname>Ebert</surname><given-names>U</given-names></name><article-title>Generation and therapeutic efficacy of highly oligomer-specific &#x003b2;-amyloid
antibodies</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>10369</fpage><lpage>10379</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5721-09.2010</pub-id><pub-id pub-id-type="pmid">20685980</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Hefti</surname><given-names>F</given-names></name><name><surname>Goure</surname><given-names>WF</given-names></name><name><surname>Jerecic</surname><given-names>J</given-names></name><name><surname>Iverson</surname><given-names>KS</given-names></name><name><surname>Walicke</surname><given-names>P</given-names></name><name><surname>Dodart</surname><given-names>J-C</given-names></name><article-title>ACU-193: a drug candidate antibody that selectively targets soluble A&#x003b2;
oligomers</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>P326</fpage></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Mulnard</surname><given-names>R</given-names></name><name><surname>Barakos</surname><given-names>J</given-names></name><name><surname>Gregg</surname><given-names>KM</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Gundman</surname><given-names>M</given-names></name><article-title>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate
Alzheimer disease</article-title><source>Neurol</source><year>2009</year><volume>73</volume><fpage>2061</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c67808</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><name><surname>Kerchner</surname><given-names>GA</given-names></name><name><surname>Boxer</surname><given-names>AL</given-names></name><article-title>Bapineuzumab</article-title><source>Expert Opin Biol Ther</source><year>2010</year><volume>10</volume><fpage>1121</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1517/14712598.2010.493872</pub-id><pub-id pub-id-type="pmid">20497044</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Mathis</surname><given-names>CA</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Barakos</surname><given-names>J</given-names></name><name><surname>Okello</surname><given-names>AA</given-names></name><name><surname>Rodriguez Martinez de Liano</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Koller</surname><given-names>M</given-names></name><name><surname>Gregg</surname><given-names>KM</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><article-title><sup>11</sup>C-PiB PET assessment of change in fibrillar amyloid-&#x003b2; load in
patients with Alzheimer&#x02019;s disease treated with bapineuzumab: a phase 1,
double-blind, placebo-controlled, ascending-dose study</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70043-0</pub-id><pub-id pub-id-type="pmid">20189881</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><name><surname>Siemers</surname><given-names>ER</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Gonzales</surname><given-names>CR</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>DeMattos</surname><given-names>RB</given-names></name><article-title>Safety and changes in plasma and cerebrospinal fluid amyloid &#x003b2; after a single
administration of an amyloid &#x003b2; monoclonal antibody in subjects with Alzheimer
disease</article-title><source>Clin Neuropharm</source><year>2010</year><volume>33</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e3181cb577a</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>Can Alzheimer disease be prevented by amyloid-&#x003b2; immunotherapy?</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.219</pub-id><pub-id pub-id-type="pmid">20140000</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Snider</surname><given-names>BJ</given-names></name><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name><name><surname>Sethuraman</surname><given-names>G</given-names></name><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Siemers</surname><given-names>ER</given-names></name><article-title>Safety and biomarker effects of solanezumab in patients with Alzheimer&#x02019;s
disease</article-title><source>Alzheimers Dement</source><year>2012</year><volume>8</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.09.224</pub-id><pub-id pub-id-type="pmid">22672770</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><name><surname>Lobello</surname><given-names>K</given-names></name><name><surname>Ryan</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Rippon</surname><given-names>G</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><article-title>Targeting beta amyloid: a clinical review of immunotherapeutic approaches in
Alzheimer&#x02019;s disease</article-title><source>Int J Alzheimers Dis</source><year>2012</year><volume>2012</volume><fpage>628070</fpage><pub-id pub-id-type="pmid">22292124</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><name><surname>Prins</surname><given-names>ND</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><article-title>Treating Alzheimer&#x02019;s disease with monoclonal antibodies: current status and
outlook for the future</article-title><source>Alzheimers Res Ther</source><year>2013</year><volume>5</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/alzrt220</pub-id><pub-id pub-id-type="pmid">24216217</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Thomas</surname><given-names>RG</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Joffe</surname><given-names>S</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Liu-Seifert</surname><given-names>H</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><article-title>Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312889</pub-id><pub-id pub-id-type="pmid">24450890</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Klunk</surname><given-names>W</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Reichert</surname><given-names>M</given-names></name><name><surname>Ketter</surname><given-names>N</given-names></name><name><surname>Nejadnik</surname><given-names>B</given-names></name><name><surname>Guenzler</surname><given-names>V</given-names></name><name><surname>Miloslavsky</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lull</surname><given-names>J</given-names></name><name><surname>Tudor</surname><given-names>IC</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Yuen</surname><given-names>E</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Brashear</surname><given-names>RH</given-names></name><article-title>Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x02019;s
disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>322</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1304839</pub-id><pub-id pub-id-type="pmid">24450891</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><name><surname>Racke</surname><given-names>MM</given-names></name><name><surname>Boone</surname><given-names>LI</given-names></name><name><surname>Hepburn</surname><given-names>DL</given-names></name><name><surname>Parsadainian</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>MT</given-names></name><name><surname>Ness</surname><given-names>DK</given-names></name><name><surname>Piroozi</surname><given-names>KS</given-names></name><name><surname>Jordan</surname><given-names>WH</given-names></name><name><surname>Brown</surname><given-names>DD</given-names></name><name><surname>Hoffman</surname><given-names>WP</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Gitter</surname><given-names>BD</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>DeMattos</surname><given-names>RB</given-names></name><article-title>Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid
precursor protein transgenic mice by immunotherapy is dependent on antibody
recognition of deposited forms of amyloid &#x003b2;</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4337-04.2005</pub-id><pub-id pub-id-type="pmid">15659599</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name><surname>Esch</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Dovey</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Schlossmacher</surname><given-names>M</given-names></name><name><surname>Whaley</surname><given-names>J</given-names></name><name><surname>Swindlehurst</surname><given-names>C</given-names></name><name><surname>McCormack</surname><given-names>R</given-names></name><name><surname>Wolfert</surname><given-names>R</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name><name><surname>Lieberbug</surname><given-names>I</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><article-title>Isolation and quantification of soluble Alzheimer&#x02019;s &#x003b2;-peptide from
biological fluids</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/359325a0</pub-id><pub-id pub-id-type="pmid">1406936</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Cummins</surname><given-names>DJ</given-names></name><name><surname>Dodart</surname><given-names>J-C</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>Peripheral anti-A&#x003b2; antibody alters CNS and plasma A&#x003b2; clearance and
decreases brain A&#x003b2; burden in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>8850</fpage><lpage>8855</lpage><pub-id pub-id-type="doi">10.1073/pnas.151261398</pub-id><pub-id pub-id-type="pmid">11438712</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Yabuki</surname><given-names>C</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Hori</surname><given-names>Y</given-names></name><name><surname>Ohtsuki</surname><given-names>S</given-names></name><name><surname>Terasaki</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><article-title>A&#x003b2; immunotherapy: intracerebral sequestration of A&#x003b2; by an anti-A&#x003b2;
monoclonal antibody 266 with high affinity to soluble A&#x003b2;</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>11393</fpage><lpage>11398</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2021-09.2009</pub-id><pub-id pub-id-type="pmid">19741145</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="other"><name><surname>Basi</surname><given-names>G</given-names></name><name><surname>Jacobsen</surname><given-names>JS</given-names></name><source>Humanized abeta antibodies for use in improving cognition</source><series>United States Patent Application Publication Number US 2006/0198851 A1</series><year>2006</year></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="book"><name><surname>Toolan</surname><given-names>D</given-names></name><name><surname>Tugusheva</surname><given-names>K</given-names></name><name><surname>Haugabook</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>McCampbell</surname><given-names>A</given-names></name><name><surname>Hatcher</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>W-Q</given-names></name><name><surname>Gretzula</surname><given-names>C-A</given-names></name><name><surname>Cash-Mason</surname><given-names>T</given-names></name><name><surname>Lemaire</surname><given-names>P</given-names></name><name><surname>Savage</surname><given-names>M</given-names></name><name><surname>Shughrue</surname><given-names>P</given-names></name><name><surname>Ray</surname><given-names>J</given-names></name><name><surname>Renger</surname><given-names>J</given-names></name><source>Characterizing the selectivity of an antibody that targets a rare and unstable
conformation of the A&#x003b2; peptide in Alzheimer&#x02019;s disease</source><year>2010</year><publisher-name>Unpublished internal research report, Merck &#x00026; Co</publisher-name><comment>[<ext-link ext-link-type="uri" xlink:href="http://www.acumenpharm.com/News/Toolan.pdf">http://www.acumenpharm.com/News/Toolan.pdf</ext-link>]</comment></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Cannon</surname><given-names>C</given-names></name><name><surname>Carretto</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>M</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Guido</surname><given-names>T</given-names></name><name><surname>Hoenow</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Johnson-Wood</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>A</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>P</given-names></name><name><surname>Vasquez</surname><given-names>N</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Yednock</surname><given-names>T</given-names></name><article-title>Epitope and isotype specificities of antibodies to &#x003b2;-amyloid peptide for
protection against Alzheimer&#x02019;s disease-like neuropathology</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>2023</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1073/pnas.0436286100</pub-id><pub-id pub-id-type="pmid">12566568</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>W</given-names></name><name><surname>Gordon</surname><given-names>G</given-names></name><name><surname>Grajeda</surname><given-names>H</given-names></name><name><surname>Guido</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Johnson-Wood</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Mutter</surname><given-names>L</given-names></name><name><surname>Soriano</surname><given-names>F</given-names></name><name><surname>Shopp</surname><given-names>G</given-names></name><name><surname>Vasquez</surname><given-names>N</given-names></name><name><surname>Vandevert</surname><given-names>C</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name><name><surname>Wogulis</surname><given-names>M</given-names></name><name><surname>Yednock</surname><given-names>T</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><article-title>Immunization with amyloid-&#x003b2; attenuates Alzheimer-disease-like pathology in
the PDAPP mouse</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/22124</pub-id><pub-id pub-id-type="pmid">10408445</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Cannon</surname><given-names>C</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>R-L</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Grajeda</surname><given-names>H</given-names></name><name><surname>Guido</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kohnson-Wood</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Soriano</surname><given-names>F</given-names></name><name><surname>Vasquez</surname><given-names>N</given-names></name><name><surname>Weiss</surname><given-names>K</given-names></name><name><surname>Welch</surname><given-names>B</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Yednock</surname><given-names>T</given-names></name><article-title>Peripherally administered antibodies against amyloid &#x003b2;-peptide enter the
central nervous system and reduce pathology in a mouse model of Alzheimer
disease</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>916</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1038/78682</pub-id><pub-id pub-id-type="pmid">10932230</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="other"><name><surname>Basi</surname><given-names>G</given-names></name><name><surname>Saldanha</surname><given-names>J</given-names></name><name><surname>Yednock</surname><given-names>T</given-names></name><source>Humanized antibodies that recognize beta amyloid peptide</source><series>World Intellectual Property Organization International Publication Number WO
02/46237 A2</series><year>2002</year></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><name><surname>Johnson-Wood</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>G</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><article-title>Amyloid precursor protein processing and A&#x003b2;<sub>42</sub> deposition in a
transgenic mouse model of Alzheimer disease</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>1550</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.4.1550</pub-id><pub-id pub-id-type="pmid">9037091</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><name><surname>Buttini</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Grajeda</surname><given-names>H</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Kohnson-Wood</surname><given-names>K</given-names></name><name><surname>Kham</surname><given-names>K</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Freedman</surname><given-names>S</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><article-title>&#x003b2;-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of
Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>9096</fpage><lpage>9101</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1697-05.2005</pub-id><pub-id pub-id-type="pmid">16207868</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><name><surname>Schroeter</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Doan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guido</surname><given-names>T</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name><name><surname>Basi</surname><given-names>G</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><article-title>Immunotherapy reduces vascular amyloid-&#x003b2; in PDAPP mice</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>6787</fpage><lpage>6793</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2377-07.2008</pub-id><pub-id pub-id-type="pmid">18596154</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Fox</surname><given-names>M</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><name><surname>Yednock</surname><given-names>T</given-names></name><article-title>Sustained levels of antibodies against A&#x003b2; in amyloid-rich regions of the CNS
following intravenous dosing in human APP transgenic mice</article-title><source>Exp Neurology</source><year>2012</year><volume>238</volume><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2012.07.022</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><article-title>Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels
in patients with mild to moderate Alzheimer disease</article-title><source>Arch Nuerol</source><year>2012</year><volume>69</volume><fpage>1002</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2012.90</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="other"><name><surname>Pfeifer</surname><given-names>A</given-names></name><name><surname>Pihlgren</surname><given-names>M</given-names></name><name><surname>Muhs</surname><given-names>A</given-names></name><name><surname>Watts</surname><given-names>R</given-names></name><source>Humanized antibodies to amyloid beta</source><series>World Intellectual Property Organization International Publication Number WO
2008/156622 A1</series><year>2008</year></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><name><surname>Adolfsson</surname><given-names>O</given-names></name><name><surname>Pihlgren</surname><given-names>M</given-names></name><name><surname>Toni</surname><given-names>N</given-names></name><name><surname>Varisco</surname><given-names>Y</given-names></name><name><surname>Buccarello</surname><given-names>AL</given-names></name><name><surname>Antoniello</surname><given-names>K</given-names></name><name><surname>Lohmann</surname><given-names>S</given-names></name><name><surname>Piorkowska</surname><given-names>K</given-names></name><name><surname>Gafner</surname><given-names>V</given-names></name><name><surname>Atwal</surname><given-names>JK</given-names></name><name><surname>Maloney</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gogineni</surname><given-names>A</given-names></name><name><surname>Weimer</surname><given-names>RM</given-names></name><name><surname>Mortensen</surname><given-names>DL</given-names></name><name><surname>Friesenhahn</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Pfeifer</surname><given-names>A</given-names></name><name><surname>Muhs</surname><given-names>A</given-names></name><name><surname>Watts</surname><given-names>RJ</given-names></name><article-title>An effector-reduced anti-&#x003b2;-amyloid (A&#x003b2;) antibody with unique A&#x003b2;
binding properties promotes neuroprotection and glial engulfment of A&#x003b2;</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>9677</fpage><lpage>9689</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4742-11.2012</pub-id><pub-id pub-id-type="pmid">22787053</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="other"><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Ponns</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>W-H</given-names></name><name><surname>Grimm</surname><given-names>JM</given-names></name><source>Antibodies directed against amyloid-beta peptide and methods using same</source><series>World Intellectual Property Organization International Publication Number WO
2006/036291 A2</series><year>2006</year></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><name><surname>Carty</surname><given-names>NC</given-names></name><name><surname>Wilcock</surname><given-names>DM</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Pons</surname><given-names>J</given-names></name><name><surname>Ronan</surname><given-names>V</given-names></name><name><surname>Gottschall</surname><given-names>PE</given-names></name><name><surname>Gordon</surname><given-names>MN</given-names></name><name><surname>Morgan</surname><given-names>D</given-names></name><article-title>Intracranial administration of deglycosyoated C-terminal-specific anti-A&#x003b2;
antibody efficiently clears amyloid plaques without activating microglia in
amyloid-depositing transgenic mice</article-title><source>J Neuroinflammation</source><year>2006</year><volume>3</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-3-11</pub-id><pub-id pub-id-type="pmid">16686956</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><name><surname>La Porte</surname><given-names>SL</given-names></name><name><surname>Bollini</surname><given-names>SS</given-names></name><name><surname>Lanz</surname><given-names>TA</given-names></name><name><surname>Abdiche</surname><given-names>YN</given-names></name><name><surname>Rusnak</surname><given-names>AS</given-names></name><name><surname>Ho</surname><given-names>W-H</given-names></name><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Harrabi</surname><given-names>O</given-names></name><name><surname>Pappas</surname><given-names>D</given-names></name><name><surname>Mina</surname><given-names>EW</given-names></name><name><surname>Milici</surname><given-names>AJ</given-names></name><name><surname>Kawbe</surname><given-names>TT</given-names></name><name><surname>Bales</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Pons</surname><given-names>J</given-names></name><article-title>Structural basis of C-terminal &#x003b2;-amyloid peptide binding by the antibody
ponezumab for treatment of Alzheimer&#x02019;s disease</article-title><source>J Mol Biol</source><year>2012</year><volume>421</volume><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.11.047</pub-id><pub-id pub-id-type="pmid">22197375</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="other"><name><surname>Nitsch</surname><given-names>R</given-names></name><name><surname>Hock</surname><given-names>C</given-names></name><name><surname>Esslinger</surname><given-names>C</given-names></name><name><surname>Knobloch</surname><given-names>M</given-names></name><name><surname>Tissot</surname><given-names>K</given-names></name><source>Method of providing disease-specific binding molecules and targets</source><series>World Intellectual Property Organization International Publication Number WO
2008/081008 A1</series><year>2008</year></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><name><surname>Dunstan</surname><given-names>R</given-names></name><name><surname>Bussiere</surname><given-names>T</given-names></name><name><surname>Rhodes</surname><given-names>K</given-names></name><name><surname>Engber</surname><given-names>T</given-names></name><name><surname>Maier</surname><given-names>M</given-names></name><name><surname>Weinreb</surname><given-names>P</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Nitsch</surname><given-names>R</given-names></name><name><surname>Arustu</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><article-title>Molecular characterization and preclinical efficacy</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>S457</fpage></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><name><surname>Englund</surname><given-names>H</given-names></name><name><surname>Sehlin</surname><given-names>D</given-names></name><name><surname>Johansson</surname><given-names>A-S</given-names></name><name><surname>Nilsson</surname><given-names>LNG</given-names></name><name><surname>Gellerfors</surname><given-names>P</given-names></name><name><surname>Paulie</surname><given-names>S</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Pettersson</surname><given-names>FE</given-names></name><article-title>Sensitive ELISA detection of amyloid-&#x003b2; protofibrils in biological samples</article-title><source>J Neurochem</source><year>2007</year><volume>103</volume><fpage>334</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">17623042</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><name><surname>Nilsberth</surname><given-names>C</given-names></name><name><surname>Westlind-Danielsson</surname><given-names>A</given-names></name><name><surname>Eckman</surname><given-names>CB</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Axelman</surname><given-names>K</given-names></name><name><surname>Forsell</surname><given-names>C</given-names></name><name><surname>Stenh</surname><given-names>C</given-names></name><name><surname>Luthman</surname><given-names>J</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>N&#x000e4;slund</surname><given-names>J</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><article-title>The &#x02018;Artic&#x02019; APP mutation (E693G) causes Alzheimer&#x02019;s disease by
enhanced A&#x003b2; protofibril formation</article-title><source>Nat Neurosci</source><year>2001</year><volume>4</volume><fpage>887</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1038/nn0901-887</pub-id><pub-id pub-id-type="pmid">11528419</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Head</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>McIntire</surname><given-names>TM</given-names></name><name><surname>Milton</surname><given-names>SC</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><article-title>Common structure of soluble amyloid oligomers implies common mechanism of
pathogenesis</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>486</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1126/science.1079469</pub-id><pub-id pub-id-type="pmid">12702875</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><name><surname>Lord</surname><given-names>A</given-names></name><name><surname>Gumucio</surname><given-names>A</given-names></name><name><surname>Englund</surname><given-names>H</given-names></name><name><surname>Sehlin</surname><given-names>D</given-names></name><name><surname>Sundquist</surname><given-names>VS</given-names></name><name><surname>S&#x000f6;derberg</surname><given-names>L</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>C</given-names></name><name><surname>Gellerfors</surname><given-names>P</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Pettersson</surname><given-names>FE</given-names></name><name><surname>Nilsson</surname><given-names>LN</given-names></name><article-title>An amyloid-&#x003b2; protofibril-selective antibody prevents amyloid formation in a
mouse model of Alzheimer&#x02019;s disease</article-title><source>Neurobiol Dis</source><year>2009</year><volume>36</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.08.007</pub-id><pub-id pub-id-type="pmid">19703562</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="other"><name><surname>Gellerfors</surname><given-names>P</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Sehlin</surname><given-names>D</given-names></name><name><surname>Pettersson</surname><given-names>FE</given-names></name><name><surname>Englund</surname><given-names>H</given-names></name><source>Protofibril selective antibodies and the use thereof</source><series>United States Patent Application Publication Number US 2009/0258009 A1</series><year>2009</year></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><name><surname>Bohrmann</surname><given-names>B</given-names></name><name><surname>Baumann</surname><given-names>K</given-names></name><name><surname>Benz</surname><given-names>J</given-names></name><name><surname>Gerber</surname><given-names>F</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Knoflach</surname><given-names>F</given-names></name><name><surname>Messer</surname><given-names>J</given-names></name><name><surname>Oroszlan</surname><given-names>K</given-names></name><name><surname>Rauchenberger</surname><given-names>R</given-names></name><name><surname>Richter</surname><given-names>WF</given-names></name><name><surname>Rothe</surname><given-names>C</given-names></name><name><surname>Urban</surname><given-names>M</given-names></name><name><surname>Bardroff</surname><given-names>M</given-names></name><name><surname>Winter</surname><given-names>M</given-names></name><name><surname>Nordstedt</surname><given-names>C</given-names></name><name><surname>Loetscher</surname><given-names>H</given-names></name><article-title>Gantenerumab: a novel human anti-A&#x003b2; antibody demonstrates sustained cerebral
amyloid-&#x003b2; binding and elicits cell-mediated removal of human
amyloid-&#x003b2;</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>28</volume><fpage>49</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">21955818</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><name><surname>Ostrowitzki</surname><given-names>S</given-names></name><name><surname>Deptula</surname><given-names>D</given-names></name><name><surname>Thurfjell</surname><given-names>L</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Bohrmann</surname><given-names>B</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Ashford</surname><given-names>E</given-names></name><name><surname>Yoo</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>Z-X</given-names></name><name><surname>Loetscher</surname><given-names>H</given-names></name><name><surname>Santarelli</surname><given-names>L</given-names></name><article-title>Mechanism of amyloid removal in patients with Alzheimer disease treated with
gantenerumab</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.1538</pub-id><pub-id pub-id-type="pmid">21987394</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><name><surname>Schupf</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name><name><surname>Manly</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>H</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>Ravetch</surname><given-names>J</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><article-title>Peripheral A&#x003b2; subspecies as risk biomarkers of Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><fpage>14052</fpage><lpage>14057</lpage><pub-id pub-id-type="doi">10.1073/pnas.0805902105</pub-id><pub-id pub-id-type="pmid">18779561</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="other"><name><surname>Ravetch</surname><given-names>J</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name><source>Antibodies specific for the protofibril form of beta-amyloid protein</source><series>World Intellectual Property Organization, International Publication Number WO
2009/065054 A3</series><year>2009</year></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><name><surname>Pradier</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Blanchard</surname><given-names>V</given-names></name><name><surname>Debeir</surname><given-names>T</given-names></name><name><surname>Barneoud</surname><given-names>P</given-names></name><name><surname>Canton</surname><given-names>T</given-names></name><name><surname>Menager</surname><given-names>J</given-names></name><name><surname>Bohme</surname><given-names>A</given-names></name><name><surname>Rooney</surname><given-names>T</given-names></name><name><surname>Guillet</surname><given-names>M-C</given-names></name><name><surname>Cameron</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Naimi</surname><given-names>S</given-names></name><name><surname>Ravetch</surname><given-names>J</given-names></name><name><surname>Claudel</surname><given-names>S</given-names></name><name><surname>Alam</surname><given-names>J</given-names></name><article-title>SAR228810: an antiprotofibrillar beta-amyloid antibody designed to reduce risk of
amyloid-related imaging abnormalities (ARIA)</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>P808</fpage><lpage>P809</lpage></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="other"><name><surname>Baurin</surname><given-names>N</given-names></name><name><surname>Blanche</surname><given-names>F</given-names></name><name><surname>Cameron</surname><given-names>B</given-names></name><name><surname>Duchesne</surname><given-names>M</given-names></name><name><surname>Mikol</surname><given-names>V</given-names></name><name><surname>Naimi</surname><given-names>S</given-names></name><name><surname>Pradier</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><source>Humanized antibodies specific to the protofibrillar form of the beta-amyloid
peptide</source><series>United States Patent Application Publication No. US 2012/0177639</series><year>2012</year></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><name><surname>Dodel</surname><given-names>R</given-names></name><name><surname>Balakrishnan</surname><given-names>K</given-names></name><name><surname>Keyvani</surname><given-names>K</given-names></name><name><surname>Deuster</surname><given-names>O</given-names></name><name><surname>Neff</surname><given-names>F</given-names></name><name><surname>Andrei-Selmer</surname><given-names>L-C</given-names></name><name><surname>R&#x000f6;skam</surname><given-names>S</given-names></name><name><surname>St&#x000fc;er</surname><given-names>C</given-names></name><name><surname>Al-Abed</surname><given-names>Y</given-names></name><name><surname>Noelker</surname><given-names>C</given-names></name><name><surname>Balzer-Geldsetzer</surname><given-names>M</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Bacher</surname><given-names>M</given-names></name><article-title>Naturally occurring autoantibodies against &#x003b2;-amyloid: investigating their
role in transgenic animal and in vitro models of Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>5847</fpage><lpage>5854</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4401-10.2011</pub-id><pub-id pub-id-type="pmid">21490226</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><name><surname>Moir</surname><given-names>RD</given-names></name><name><surname>Tseitlin</surname><given-names>KA</given-names></name><name><surname>Soscia</surname><given-names>S</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Irizarry</surname><given-names>MC</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><article-title>Autoantibodies to redox-modified oligomeric A&#x003b2; are attenuated in the plasma
of Alzheimer&#x02019;s disease patients</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>17458</fpage><lpage>17463</lpage><pub-id pub-id-type="doi">10.1074/jbc.M414176200</pub-id><pub-id pub-id-type="pmid">15728175</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><name><surname>Szabo</surname><given-names>P</given-names></name><name><surname>Relkin</surname><given-names>N</given-names></name><name><surname>Weksler</surname><given-names>ME</given-names></name><article-title>Natural human antibodies to amyloid beta peptide</article-title><source>Autoimmunity Rev</source><year>2008</year><volume>7</volume><fpage>415</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2008.03.007</pub-id><pub-id pub-id-type="pmid">18558354</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Fernandez</surname><given-names>S</given-names></name><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Khuon</surname><given-names>D</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Shaw</surname><given-names>P</given-names></name><name><surname>De Felice</surname><given-names>FG</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><article-title>Monoclonal antibodies that target pathological assemblies of A&#x003b2;</article-title><source>J Neurochem</source><year>2007</year><volume>100</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04157.x</pub-id><pub-id pub-id-type="pmid">17116235</pub-id></mixed-citation></ref></ref-list></back></article>